<SEC-DOCUMENT>0001410578-19-001349.txt : 20190920
<SEC-HEADER>0001410578-19-001349.hdr.sgml : 20190920
<ACCEPTANCE-DATETIME>20190920163643
ACCESSION NUMBER:		0001410578-19-001349
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20190916
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190920
DATE AS OF CHANGE:		20190920

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			uniQure N.V.
		CENTRAL INDEX KEY:			0001590560
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36294
		FILM NUMBER:		191105125

	BUSINESS ADDRESS:	
		STREET 1:		PAASHEUVELWEG 25A
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1105 BP
		BUSINESS PHONE:		1-339-970-7000

	MAIL ADDRESS:	
		STREET 1:		PAASHEUVELWEG 25A
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1105 BP

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	uniQure B.V.
		DATE OF NAME CHANGE:	20131030
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tv529829_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:qure="http://uniqure.com/20190916">
<head>
     <title></title>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_021_US%2DGAAP%2D2019 -->
<!-- Field: Set; Name: xdx; ID: xdx_033_qure_uniqure.com_20190916 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20190915_20190916 -->
<!-- Field: Set; Name: xdx; ID: xdx_053_edei%2D%2DEntityCentralIndexKey_0001590560 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
  <ix:hidden>
    <ix:nonNumeric contextRef="From2019-09-15to2019-09-16" name="dei:EntityCentralIndexKey">0001590560</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2019-09-15to2019-09-16" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    </ix:hidden>
  <ix:references>
    <link:schemaRef xlink:href="qure-20190916.xsd" xlink:type="simple" />
    </ix:references>
  <ix:resources>
    <xbrli:context id="From2019-09-15to2019-09-16">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001590560</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-09-15</xbrli:startDate>
        <xbrli:endDate>2019-09-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    </ix:resources>
  </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0"><b>&#160;</b></p>

<p style="font: 16pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES<br />
SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 16pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 16pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM&#160;<span id="xdx_902_edei--DocumentType_c20190915__20190916_zfXq5zwHKIB2"><ix:nonNumeric contextRef="From2019-09-15to2019-09-16" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section&#160;13 or 15(d)&#160;of
the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<b><span id="xdx_900_edei--DocumentPeriodEndDate_c20190915__20190916_z3UAhSr7Njqi"><ix:nonNumeric contextRef="From2019-09-15to2019-09-16" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">September 16, 2019</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 16pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_902_edei--EntityRegistrantName_c20190915__20190916_zfHy2iAVcakj"><ix:nonNumeric contextRef="From2019-09-15to2019-09-16" name="dei:EntityRegistrantName">uniQure N.V.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in
Charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: top; width: 32%; text-align: center"><span style="font-size: 10pt"><b>The <span id="xdx_901_edei--EntityIncorporationStateCountryCode_c20190915__20190916_zXuUh26nRoKl"><ix:nonNumeric contextRef="From2019-09-15to2019-09-16" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode">Netherlands</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90F_edei--EntityFileNumber_c20190915__20190916_zhTC1svJEHCj"><ix:nonNumeric contextRef="From2019-09-15to2019-09-16" name="dei:EntityFileNumber">001-36294</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 32%; text-align: center"><span style="font-size: 10pt"><b>N/A</b></span></td></tr>
<tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(State or Other<br />
Jurisdiction of Incorporation)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(Commission<br />
File Number)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(IRS Employer<br />
Identification No.)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: top; width: 49%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90E_edei--EntityAddressAddressLine1_c20190915__20190916_zWEkqmYiP2N3"><ix:nonNumeric contextRef="From2019-09-15to2019-09-16" name="dei:EntityAddressAddressLine1">Paasheuvelweg 25a</ix:nonNumeric></span>,</b><br />
<b><span id="xdx_901_edei--EntityAddressPostalZipCode_c20190915__20190916_z5oJhxvaYS3b"><ix:nonNumeric contextRef="From2019-09-15to2019-09-16" name="dei:EntityAddressPostalZipCode">1105 BP</ix:nonNumeric></span> <span id="xdx_904_edei--EntityAddressCityOrTown_c20190915__20190916_zHRUxt4RkAyc"><ix:nonNumeric contextRef="From2019-09-15to2019-09-16" name="dei:EntityAddressCityOrTown">Amsterdam</ix:nonNumeric></span>, The <span id="xdx_908_edei--EntityAddressCountry_c20190915__20190916_zI5cZ3xKnRS8"><ix:nonNumeric contextRef="From2019-09-15to2019-09-16" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry">Netherlands</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="vertical-align: bottom; width: 49%; text-align: center"><span style="font-size: 10pt"><b>N/A</b></span></td></tr>
<tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(Address of Principal Executive Offices)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(Zip Code)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
area code: <b>+<span id="xdx_902_edei--CityAreaCode_c20190915__20190916_zqL08h8yGdE2"><ix:nonNumeric contextRef="From2019-09-15to2019-09-16" name="dei:CityAreaCode">31</ix:nonNumeric></span>-<span id="xdx_902_edei--LocalPhoneNumber_c20190915__20190916_zwbKDCMtWPP6"><ix:nonNumeric contextRef="From2019-09-15to2019-09-16" name="dei:LocalPhoneNumber">20-566-7394</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former Name or Former Address, if Changed
Since Last Report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36.3pt; text-align: justify">Check the appropriate box below if the
Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(<i>see</i> General Instruction A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_90E_edei--WrittenCommunications_c20190915__20190916_zt1TsCuMsFZ3"><ix:nonNumeric contextRef="From2019-09-15to2019-09-16" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;Written communications
pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_900_edei--SolicitingMaterial_c20190915__20190916_zBg02ciQNafg"><ix:nonNumeric contextRef="From2019-09-15to2019-09-16" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;Soliciting material
pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_902_edei--PreCommencementTenderOffer_c20190915__20190916_zxRdQzFTBIml"><ix:nonNumeric contextRef="From2019-09-15to2019-09-16" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pre-commencement
communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_90A_edei--PreCommencementIssuerTenderOffer_c20190915__20190916_zrJ1gGla47zf"><ix:nonNumeric contextRef="From2019-09-15to2019-09-16" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under
the Exchange Act (17 CFR&#9;240.13e-4(c))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: bottom; width: 32%; border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Title&#160;of&#160;each&#160;class:</b></span></td>
    <td style="vertical-align: top; width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 32%; border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Trading Symbol(s)</b></span></td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="vertical-align: bottom; width: 32%; border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered:</b></span></td></tr>
<tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><span id="xdx_909_edei--Security12bTitle_c20190915__20190916_zYLqZa0hw1f8"><ix:nonNumeric contextRef="From2019-09-15to2019-09-16" name="dei:Security12bTitle">Ordinary Shares, par value &#8364;0.05 per share</ix:nonNumeric></span></span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><span id="xdx_90C_edei--TradingSymbol_c20190915__20190916_z6BJuokf4nv1"><ix:nonNumeric contextRef="From2019-09-15to2019-09-16" name="dei:TradingSymbol">QURE</ix:nonNumeric></span></span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><span id="xdx_907_edei--SecurityExchangeName_c20190915__20190916_zKTiiueoPKBj"><ix:nonNumeric contextRef="From2019-09-15to2019-09-16" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The Nasdaq Global Select Market</ix:nonNumeric></span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of
the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <span style="font-family: Wingdings"><span id="xdx_905_edei--EntityEmergingGrowthCompany_c20190915__20190916_zkplbryiyKo"><ix:nonNumeric contextRef="From2019-09-15to2019-09-16" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family: Wingdings">&#168;</span></p>



<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Item 5.02&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Departure of Directors or
Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers</b></p>



<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As previously disclosed on a current report
on Form 8-K filed by uniQure N.V. (the &#8220;Company&#8221;) on August 26, 2019, the Company promoted Alex Kuta, Ph.D. to Executive
Vice President, Operations and Sander van Deventer, M.D., Ph.D. to Executive Vice President, Research and Product Development,
effective August 20, 2019 (such promotions are collectively referred to herein as the &#8220;Leadership Promotions&#8221;). In
connection with the Leadership Promotions, the Company eliminated the position of chief operating officer. As a result, Scott McMillan,
Ph.D., the Company&#8217;s current chief operating officer, retired from the Company, effective August 31, 2019. In connection
with the foregoing, the Company entered into various agreements, as detailed below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration: underline">Dr. Kuta</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Amended and Restated Employment
Agreement, executed on September 17, 2019, but effective as of August 20, 2019, by and between the Company and Dr. Kuta (the &#8220;Kuta
Agreement&#8221;), Dr. Kuta will receive a gross base salary of approximately $430,000 (the &#8220;Kuta Base Salary&#8221;). The
Kuta Agreement also provides for terms of benefits afforded to Dr. Kuta, including the ability to participate in various group
insurance plans, reimbursement for necessary and reasonable business expenses, liability insurance and vacation time. Additionally,
Dr. Kuta is eligible for a target retention and performance bonus of up to forty-percent (40%) of the Kuta Base Salary, as determined
by the Company in its sole discretion (the &#8220;Kuta Discretionary Bonus Amount&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, on September 17, 2019 Dr.
Kuta also received a grant of fifteen thousand (15,000) restricted stock units, which such grant will vest over a period of
three years beginning on the first anniversary of the date of grant, subject to Dr. Kuta&#8217;s continued relationship with
the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Kuta Agreement, if Dr.
Kuta&#8217;s employment is terminated due to his death or Disability, for Cause or upon the resignation of Dr. Kuta without Good
Reason, then Dr. Kuta will be entitled only to Accrued Benefits through such termination date. If Dr. Kuta resigns for Good Reason
or if his employment with the Company is terminated by the Company without Cause, then Dr. Kuta will be entitled to: (i) Accrued
Benefits through the date of such termination, (ii) a lump sum severance payment equal to the sum of (a) the Kuta Base Salary and
(b) the Kuta Discretionary Bonus Amount, (iii) a bonus pro-rated to the date of termination and based on the Kuta Discretionary
Bonus Amount and (iv) continued coverage through COBRA until the earlier of (a) twelve (12) months from the date of termination,
(b) the date on which Dr. Kuta becomes eligible to participate in another employer&#8217;s group health plan, (c) the date on which
Dr. Kuta is no longer eligible for COBRA coverage or (d) the date on which the Company in good faith determines that payments would
result in a discriminatory health plan pursuant to the Patient Protection and Affordable Care Act of 2010.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, if Dr. Kuta&#8217;s employment
is terminated as a result of a Change of Control Termination, then Dr. Kuta will be entitled to: (i) Accrued Benefits through date
of such termination, (ii) a lump sum severance payment equal to one-hundred and fifty percent (150%) of the sum of (a) the Kuta
Base Salary and (b) the Kuta Discretionary Bonus Amount, (iii) a bonus pro-rated to the date of termination and based on the Discretionary
Bonus Amount and (iv) continued coverage through COBRA until the earlier of (a) eighteen (18) months, (b) the date on which Dr.
Kuta becomes eligible to participate in another employer&#8217;s group health plan, (c) the date on which Dr. Kuta is no longer
eligible for COBRA coverage or (d) the date on which the Company in good faith determines that payments would result in a discriminatory
health plan pursuant to the Patient Protection and Affordable Care Act of 2010.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, upon a Change of Control,
any vesting conditions applicable to any options, restricted shares, restricted stock units, performance stock units or other grants
of equity held by Dr. Kuta under the Company&#8217;s equity plans will be automatically waived, and all the stock options will
be deemed to be fully exercisable commencing on the date of the Change of Control and ending on the eighteen (18) month anniversary
of the Change of Control or, if earlier, the expiration of the term of such stock options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Kuta Agreement, Dr. Kuta
is subject to customary non-competition and non-solicitation covenants during the term of the Kuta Agreement under a Confidentiality,
Developments and Restrictive Covenants Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration: underline">Dr. van Deventer</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to an employment arrangement
by and between the Company and Dr. van Deventer, executed on September 17, 2019 but effective as of August 20, 2019 (the
&#8220;van Deventer Agreement&#8221;), which replaces and supersedes Dr. van Deventer&#8217;s prior employment agreement with
the Company, Dr. van Deventer will receive a gross base salary of approximately &#8364;348,000, which reflects Dr. van
Deventer&#8217;s part-time (0.8 FTE) position with the Company (the &#8220;van Deventer Base Salary&#8221;). The van Deventer
Agreement also provides for terms of benefits afforded to Dr. van Deventer, including the ability to participate in the
Company&#8217;s pension scheme, reimbursement for reasonable business expenses and vacation time. Additionally, Dr. van
Deventer is eligible for a target retention and performance bonus of up to forty-percent (40%) of the van Deventer Base
Salary, as determined by the Company in its sole discretion (the &#8220;van Deventer Discretionary Bonus Amount&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, on September 17, 2019 Dr.
van Deventer also received a grant of fifteen thousand (15,000) restricted stock units, which such grant will vest over a
period of three years beginning on the first anniversary of the date of grant, subject to Dr. van Deventer&#8217;s continued
relationship with the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The van Deventer Agreement also provides
that if the van Deventer Agreement is terminated on the initiative of Dr. van Deventer (other than in the case of summary dismissal,
long-term illness or severely culpable acts or omissions by Dr. van Deventer, as referenecd in the applicable provision of the
Dutch Civil Code (collectively, the &#8220;Carve-out Events&#8221;)), Dr. van Deventer will be eligible to receive a lump sum severance
payment equal to the sum of (i) the van Deventer Base Salary, excluding 8% holiday allowance, and (ii) the van Deventer Bonus Amount,
excluding holiday allowance, subject to deductions that are authorized by Dr. van Deventer and/or required by applicable laws and
regulations. If the van Deventer Agreement is terminated on the initiative of the Company within twelve (12) months of a Change
of Control (other than in the case of a Carve-out Event), Dr. van Deventer will be eligible to receive a lump sum severance payment
equal to one-hundred and fifty precent (150%) of the sum of (i) the van Deventer Base Salary, excluding 8% holiday allowance, and
(ii) the van Deventer Bonus Amount, excluding holiday allowance, subject to deductions that are authorized by Dr. van Deventer
and/or required by applicable laws and regulations. Dr. van Deventer is also eligible for additional severance in an amount equal
to the van Deventer Discretionary Bonus Amount, pro-rated to the date of termination, if such termination occurs as a result of
a Change of Control or on the initiative of Dr. van Deventer (other than in the case of a Carve-out Event).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, upon a Change of Control,
any vesting conditions applicable to any options, restricted shares, restricted stock units, performance stock units or other grants
of equity held by Dr. van Deventer under the Company&#8217;s equity plans will be automatically waived, and all the stock options
will be deemed to be fully exercisable commencing on the date of the Change of Control and ending on the eighteen (18) month anniversary
of the Change of Control or, if earlier, the expiration of the term of such stock options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration: underline">McMillan Separation Agreement</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 16, 2019, the Company entered
into a separation agreement with Dr. McMillan (the &#8220;Separation Agreement&#8221;) in connection with Dr. McMillan&#8217;s
retirement from the Company, effective as of August 31, 2019 (the &#8220;Separation Date&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Separation Agreement provides that
Dr. McMillan will receive, subject to the terms thereof, a lump sum severance payment equal to 100% of Dr. McMillan&#8217;s annual
base salary, or approximately $392,000, less applicable taxes and withholdings, within 30 days following the execution of the Separation
Agreement and, upon Dr. McMillan&#8217;s election, reimbursement of full COBRA premiums until the earlier of (a) eighteen (18)
months from the Separation Date, (b) the date on which Dr. McMillan becomes eligible to participate in another employer&#8217;s
group health plan, (c) the date on which Dr. McMillan (or his eligible dependents, as applicable) is no longer eligible for COBRA
coverage or (d) the date on which the Company in good faith determines that payments would result in a discriminatory health plan
pursuant to the Patient Protection and Affordable Care Act of 2010. In addition, Dr. McMillan also received all of his base salary
through the Separation Date and was paid for any accrued but unused paid time off as of the Separation Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Separation Agreement, Dr.
McMillan&#8217;s participation in all of the Company&#8217;s employee benefit plans terminated as of the Separation Date. All equity
incentive awards previously granted to Dr. McMillan will continue to be governed by the terms and conditions of their respective
award agreements, except with respect to 7,045 Performance Share Units granted to Dr. McMillan in January 2018, which will have
a vesting date of September 19, 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Separation Agreement
also provides that, starting on September 1, 2019 and continuing until October 31, 2019, Dr. McMillan will provide
consulting services to the Company relating to the transition of his former duties, responsibilities and authorities for
payments totaling approximately $13,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. McMillan has also agreed to a full
and final release of all legal claims against the Company and certain other released parties and is subject to certain confidentiality,
disclosure and assignment of inventions, non-competition, non-solicitation restrictions pursuant to Confidentiality, Developments,
and Restrictive Covenants Agreement to which Dr. McMillan is a party.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing summaries of the Kuta Agreement,
the van Deventer Agreement and the Separation Agreement (together, the &#8220;Agreements&#8221;) do not purport to be complete
and are subject to, and are qualified in their entirety by, each of the Agreements, copies of which are attached hereto as Exhibits
10.1, 10.2 and 10.3, and which are incorporated herein by reference. Capitalized terms used above without definition have the meanings
given such terms in the applicable Agreements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"><b>Item 9.01</b></td><td><b>Financial Statements and Exhibits</b></td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibit</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 1in; text-align: center"><span style="font-size: 10pt">Exhibit No.</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Description</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><a href="tv529829_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">10.1</span></a></td>
    <td><a href="tv529829_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Amended and Restated Employment Agreement, executed September 17, 2019, by and between the Company and Dr. Kuta</span></a></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><a href="tv529829_ex10-2.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">10.2</span></a></td>
    <td><a href="tv529829_ex10-2.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Employment Agreement, executed September 17, 2019, by and between the Company and Dr. Sander van Deventer</span></a></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><a href="tv529829_ex10-3.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">10.3</span></a></td>
    <td><a href="tv529829_ex10-3.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Separation Agreement, executed September 16, 2019, by and between the Company and Dr. Scott McMillan</span></a></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center">104</td>
    <td>Cover Page formatted in Inline XBRL</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;<b>&#160;</b></i></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-size: 10pt"><b>UNIQURE N.V. </b></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 50%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 4%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 46%"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Date: September 20, 2019</span></td>
    <td><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">/S/ MATTHEW KAPUSTA</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Matthew Kapusta</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Executive Officer and Chief Financial Officer</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <!-- Field: /Page -->



<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKwjAMRb9g/xD6LNpNFN2jQ0WcImOIr8VFKW7NSOt0n+Rf2m2IIRCSe0+uECOxpY0ukeGyylLIsapL5RAyvCGjuaJ3JLt9DH5meNfWsTKuX39gQp5Bz8zG8urvvbPRFosY5GISzSfhEuQ0liGcDiLo9ITMTRdonFYlKFPAialmjU5xO3zI1ZsMVW2fdEa2mkwM4VgO8gciGUZwpEa9iB8W0jQRwaivQGyZnnUX87SOKliXWPksO6D/Dr7fYUkc -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>tv529829_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><I>Confidential</I></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>EMPLOYMENT AGREEMENT</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT
(this &ldquo;<U>Agreement</U>&rdquo;) is made and entered into as of August 20, 2019 (the &ldquo;<U>Effective Date</U>&rdquo;),
by and between uniQure, Inc., 113 Hartwell Avenue, Lexington, MA 02421 (together with any and all of its affiliates, the &ldquo;<U>Company</U>&rdquo;)
and Alex Kuta of 293 Willis Road, Sudbury, MA 01776 (the &ldquo;<U>Executive</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>WITNESSETH:</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">WHEREAS, the Company has employed Executive
as Senior Vice President, Regulatory Affairs pursuant to an Employment Agreement dated January 23, 2017 (the &ldquo;Prior Employment
Agreement&rdquo;), and now wishes to employ executive as its Executive Vice President, Operations pursuant to a new Employment
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">WHEREAS, Executive wishes to be employed
by the Company in that role and to serve in such capacity under the terms and conditions set forth in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">WHEREAS, the Company and Executive desire
to terminate the Prior Employment Agreement and contemporaneously replace the Prior Employment Agreement with this Agreement without
out any overlap, gap or discontinuity in the employment of the Executive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">NOW, THEREFORE, in consideration of the
mutual promises and covenants contained herein and intending to be legally bound hereby, the Company and Executive agree as follows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Employment.</U> The Company hereby agrees to continue to employ Executive, and Executive hereby accepts such continued
employment by the Company, as a full-time employee for the period and upon the terms and conditions contained in this Agreement.
The Prior Employment Agreement is hereby terminated as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Term.</U> Executive&rsquo;s term of employment with the Company under this Agreement shall begin on the Effective Date,
and shall continue in force and effect from year to year unless terminated earlier in accordance with Section 19 (the &ldquo;<U>Term</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Position and Duties.</U> During the Term, Executive shall serve the Company as its Executive Vice President, Operations,
reporting directly to the uniQure Chief Executive Officer (the &ldquo;<U>CEO</U>&rdquo;). Executive&rsquo;s duties will include
but not be limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD STYLE="text-align: justify">Designing and implementing uniQure&rsquo;s global GMP-manufacturing,
quality and regulatory programs and strategies;</TD>
</TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD STYLE="padding-right: 0.05in; text-align: justify">Managing pharmaceutical product manufacture according to Food and Drug Administration (FDA) guidelines,
Good Manufacturing Practices (GMP) requirements for clinical trials of Investigational New Drugs (IND) and approved New Drug Applications
(NDA) materials;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD STYLE="padding-right: 0.05in; text-align: justify">Overseeing optimization of existing products manufacturing; assuring compliance with GMP regulations;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD STYLE="padding-right: 0.05in; text-align: justify">Supporting the development of CMC regulatory filings related to the Lexington Manufacturing facility;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0">Initials<U>&nbsp;&nbsp;AK&nbsp;&nbsp;</U></P></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD>&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right; font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font: italic 10pt Times New Roman, Times, Serif">Confidential</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD STYLE="padding-right: 0.05in; text-align: justify">Timely and compliant execution of the related activities in the relevant areas and identification
of opportunities for continuous improvement, including compliance with both GMP regulations, as well as environmental and safety
regulations;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD STYLE="padding-right: 0.05in; text-align: justify">Managing the technology transfer process between the Amsterdam and Lexington facilities;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD STYLE="padding-right: 0.05in; text-align: justify">Managing capital investment and maintenance activities related to manufacturing, utilities and
equipment;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD STYLE="padding-right: 0.05in; text-align: justify">Establishing site Quality requirements and directs ongoing development and operations of the
Quality Unit, the compliance function and the GxP Quality Management System globally;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD STYLE="padding-right: 0.05in; text-align: justify">Ensuring company-wide compliance with applicable Quality regulations;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD STYLE="padding-right: 0.05in; text-align: justify">Supervising the development and presentation of periodic reports describing uniQure&rsquo;s compliance
trends and identifying areas of potential risk;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD STYLE="padding-right: 0.05in; text-align: justify">Directing the Quality oversight of GLP/GCP/GVP and bio-analytical activities (including internal
or external audit observations and development of adverse trends) to ensure patient safety and data integrity;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD STYLE="padding-right: 0.05in; text-align: justify">Working closely and collaboratively with Program Management in the execution of R&amp;D stage-gates;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD STYLE="padding-right: 0.05in; text-align: justify">Overseeing the development and submission of regulatory dossiers globally and lead the preparation
of effective and persuasive presentations and submissions to regulatory authorities and accountable for regulatory inspections
and compliance audits;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD STYLE="padding-right: 0.05in; text-align: justify">Ensuring successful negotiation strategies and execution of interactions with regulatory agencies
in the U.S., Europe and elsewhere, notably with global regulatory agencies;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD STYLE="padding-right: 0.05in; text-align: justify">Reviewing and endorsing key development documents;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD STYLE="padding-right: 0.05in; text-align: justify">Proposing Regulatory consultancies/advisory boards based on clear objectives and supports the
conduct of such processes;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD STYLE="padding-right: 0.05in; text-align: justify">Participating in leadership team meetings, Board meetings and other key operating mechanisms
required of senior management and by the Chief Executive Officer;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD STYLE="padding-right: 0.05in; text-align: justify">Developing budgets for relevant functional responsibilities, subject to approval by the Chief
Executive Officer and Chief Accounting Officer, and ensure execution within approved targets;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD STYLE="padding-right: 0.05in; text-align: justify">Fostering and developing an innovative and productive organization of talented employees, including
the management, motivation, recruitment and evaluation of personnel;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD STYLE="padding-right: 0.05in; text-align: justify">Defining, implementing, maintaining and continually improving processes and systems, supported
by meaningful Key Performance Indicators (KPI&rsquo;s);</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD STYLE="padding-right: 0.05in; text-align: justify">Interacting with staff of other disciplines, such as Finance, Research &amp; Product Development,
Human Resources, Legal, Business Development, Investor Relations and Clinical Development to ensure efficient day-to-day cooperation
and success for the business; and</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD STYLE="padding-right: 0.05in; text-align: justify">Performing other duties as may from time to time be assigned by the Company and which are commensurate
with senior executive status.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 1.4in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A comprehensive job description is being provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0">Initials<U>&nbsp;&nbsp;AK&nbsp;&nbsp;</U></P></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD>&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right; font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font: italic 10pt Times New Roman, Times, Serif">Confidential</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>During the Term, Executive shall devote full business time, best efforts, skill, knowledge, attention and energies to the
advancement of the Company&rsquo;s business and interests and to the performance of Executive&rsquo;s duties and responsibilities
as an employee of the Company. Executive shall abide by the rules, regulations, instructions, personnel practices and policies
of the Company and any changes therein that may be adopted from time to time by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="color: #070C0B">5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>During the Term, Executive shall not be <FONT STYLE="color: #070C0B">engaged in any business activity which, in the
judgment of the Company, conflicts with Executive&rsquo;s duties hereunder, whether or not such activity is pursued for pecuniary
advantage. Should Executive wish to provide any services to any other person or entity other than the Company or to serve on the
board of directors of any other entity or organization, Executive shall submit a written request to the Company for consideration
and approval by the Company, which approval shall not unreasonably be withheld. If the Company later makes a reasonable, good faith
determination that Executive&rsquo;s continued service on another entity&rsquo;s board would be detrimental to the Company, it
will give Executive thirty (30) days&rsquo; written notice that it is revoking the original approval, and Executive will resign
from the applicable board within thirty (30) days after receipt of such notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="color: #070C0B">6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Location</U>. Executive shall perform the services hereunder from the Company&rsquo;s <FONT STYLE="color: #070C0B">USA
headquarters at 113 Hartwell Avenue, Lexington MA, USA; provided, however, that Executive shall be required to travel from time
to time for business purposes, including, without limitation, to the Company&rsquo;s facilities in Amsterdam, Netherlands.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.4in 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Compensation and Benefits</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.15in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify"><I>Base Salary. </I>For all services rendered by Executive
under this Agreement, the Company will pay him a base salary at the annual rate of Four Hundred Twenty Nine Thousand Six Hundred
Forty Six Dollars (US $ 429,646), which shall be reviewed annually by the CEO for adjustment (the base salary in effect at any
time, the &ldquo;<U>Base Salary</U>&rdquo;). Executive&rsquo;s Base Salary shall be paid in bi-weekly installments, less withholdings
as required by law and deductions authorized by Executive, and payable pursuant to the Company&rsquo;s regular payroll practices
in effect at the time and as may be changed from time to time.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.15in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify"><I>Discretionary Bonus. </I>Following the end of each
calendar year and subject to the approval of the Company, Executive shall be eligible for a target retention and performance bonus
of up to forty percent (40%) of the annual Base Salary based on performance and the Company&rsquo;s performance and financial
condition during the applicable calendar year, as determined by the Company in its sole discretion (a &ldquo;<U>Bonus</U>&rdquo;).
In any event, Executive must be an active employee of the Company on the 1st of October of the relevant calendar year and on the
date the Bonus is distributed in order to be eligible for and to earn any Bonus, as it also serves as an incentive to remain employed
by the Company.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0">Initials<U>&nbsp;&nbsp;AK&nbsp;&nbsp;</U></P></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD>&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right; font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font: italic 10pt Times New Roman, Times, Serif">Confidential</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="color: #2B2B2B">8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Equity</U>. <FONT STYLE="color: #2B2B2B">Subject to Board of Directors approval at the next regularly scheduled
uniQure N.V. Board meeting after execution of this Agreement, Executive shall be granted 15,000 (fifteen thousand) Restricted Stock
Units of the Company, the terms of which shall reflect the standard three-year vesting and other terms and conditions contained
in the </FONT>uniQure <FONT STYLE="color: #2B2B2B">N.V.'s Amended and Restated 2014 Share Incentive Plan. Such option will be approved
by the Board of Directors of uniQure N.V. not later than at its next regularly scheduled meeting. If the Board fails to make the
grant at such regularly scheduled meeting, it shall be deemed a Good Reason event under Section 19(f) hereof. The Executive will
be eligible for future equity grants pursuant to the Company's policies and procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Retirement and Welfare Benefits</U>. Executive is eligible to participate in any and all benefit programs that the Company
establishes and makes available to its employees from time to time, provided that Executive is eligible under (and subject to all
provisions of) the plan documents that govern those programs. These include medical, dental and disability insurances. Benefits
are subject to change at any time in the Company&rsquo;s sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Paid Time Off and Holidays</U>. Executive is eligible for a (pro-rated) maximum of 4 weeks of paid vacation per calendar
year to be taken at such times as may be approved in advance by the Company. Executive is also entitled to all paid holidays observed
by the Company in the United States. Executive shall have all rights and be subject to all obligations and responsibilities with
respect to paid time off and holidays as are set forth in the Company&rsquo;s employee manual or other applicable policies and
procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">11.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Expense Reimbursement</U>. During the Term, Executive shall be reimbursed by the Company for all necessary and reasonable
expenses incurred by Executive in connection with the performance of Executive&rsquo;s duties hereunder (including business trips
to the uniQure Amsterdam headquarters). Executive shall keep an itemized account of such expenses, together with vouchers and/or
receipts verifying the same, and submit for reimbursement on a monthly basis. Any such expense reimbursement will be made in accordance
with the Company&rsquo;s travel and expense policies governing reimbursement of expenses as are in effect from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">12.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Withholding</U>. All amounts set forth in this Agreement are on a gross, pre-tax basis and shall be subject to all applicable
federal, state, local and foreign withholding, payroll and other taxes, and the Company may withhold from any amounts payable to
Executive (including any amounts payable pursuant to this Agreement) in order to comply with such withholding obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">13.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>IP and Restrictive Covenants</U>. The Company&rsquo;s agreement to enter into this Agreement is contingent upon Executive&rsquo;s
execution of the Company&rsquo;s Confidentiality, Developments, and Restrictive Covenants Agreement, attached as <U>Exhibit A
</U>to this Agreement. Nothing in this Agreement or the Confidentiality, Developments, and Restrictive Covenants Agreement shall
prohibit or restrict Executive from initiating communications directly with, responding to any inquiry from, providing testimony
before, providing confidential information to, reporting possible violations of law or regulation to, or filing a claim or assisting
with an investigation directly with a self-regulatory authority or a government agency or entity, including the Equal Employment
Opportunity Commission, the Department of Labor, the National Labor Relations Board, the Department of Justice, the Securities
and Exchange Commission, Congress, any agency Inspector General or any other federal, state or local regulatory authority (collectively,
the &ldquo;<U>Regulators</U>&rdquo;), or from making other disclosures that are protected under the whistleblower provisions of
state or federal law or regulation. Executive does not need the prior authorization of the Company to engage in conduct protected
by this subsection, and Executive does not need to notify the Company that Executive has engaged in such conduct. Please take
notice that federal law provides criminal and civil immunity to federal and state claims for trade secret misappropriation to
individuals who disclose trade secrets to their attorneys, courts, or government officials in certain, confidential circumstances
that are set forth at 18 U.S.C. &sect;&sect; 1833(b)(1) and 1833(b)(2), related to the reporting or investigation of a suspected
violation of the law, or in connection with a lawsuit for retaliation for reporting a suspected violation of the law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0">Initials<U>&nbsp;&nbsp;AK&nbsp;&nbsp;</U></P></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD>&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right; font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font: italic 10pt Times New Roman, Times, Serif">Confidential</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">14.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>At-Will Employment</U>. This Agreement shall not be construed as an agreement, either express or implied, to employ Executive
for any stated term, and shall in no way alter the Company&rsquo;s policy of employment at-will, under which both the Company and
Executive remain free to end the employment relationship for any reason, at any time, with or without Cause or notice. Similarly,
nothing in this Agreement shall be construed as an agreement, either express or implied, to pay Executive any compensation or grant
Executive any benefit beyond the end of employment with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">15.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Conflicting Agreements</U>. Executive acknowledges and represents that by executing this Agreement and performing Executive&rsquo;s
obligations under it, Executive will not breach or be in conflict with any other agreement to which Executive is a party or is
bound, and that Executive is not subject to any covenants against competition or similar covenants that would affect the performance
of Executive&rsquo;s obligations for the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">16.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Prior Representations</U>. This Agreement and its exhibits constitute all the terms of Executive&rsquo;s hire and
supersedes all prior representations or understandings, whether written or oral, relating to the terms and conditions of Executive&rsquo;s
employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-indent: 0.5in; text-align: justify">17.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Change of Control</U>. In the event of a Change of Control as defined below, the vesting conditions that may apply to
any options, restricted shares, restricted stock units, performance stock units or other grants of equity held by Executive pursuant
to this Agreement and the Company&rsquo;s Amended and Restated 2014 Share Incentive Plan will be automatically waived, and all
the Stock Options will be deemed to be fully exercisable commencing on the date of the Change of Control and ending on the eighteen
(18) month anniversary of the Change of Control or, if earlier, the expiration of the term of such Stock Options. For purposes
of this Agreement, &ldquo;<U>Change of Control</U>&rdquo; shall mean the date on which any of the following events occurs:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.15in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">any &ldquo;person,&rdquo; as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended
(the &ldquo;<U>Act</U>&rdquo;) (other than the Company, any of its subsidiaries, or any trustee, fiduciary or other person or entity
holding securities under any employee benefit plan or trust of the Company or any of its subsidiaries), together with all &ldquo;affiliates&rdquo;
and &ldquo;associates&rdquo; (as such terms are defined in Rule 12b-2 under the Act) of such person, shall become the &ldquo;beneficial
owner&rdquo; (as such term is defined in Rule 13d-3 under the Act), directly or indirectly, of securities of the Company representing
forty (40) percent or more of the combined voting power of the Company&rsquo;s then outstanding securities having the right to
vote in an election of the Board (&ldquo;<U>Voting Securities</U>&rdquo;) (in such case other than as a result of an acquisition
of securities directly from the Company); or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0">Initials<U>&nbsp;&nbsp;AK&nbsp;&nbsp;</U></P></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD>&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right; font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font: italic 10pt Times New Roman, Times, Serif">Confidential</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.15in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">a majority of the members of the Board is replaced during any 12-month period by directors whose appointment or election is
not endorsed by a majority of the members of the Board before the date of the appointment or election; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.15in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">the consummation of (i) any consolidation or merger of the Company where the stockholders of the Company, immediately prior
to the consolidation or merger, would not, immediately after the consolidation or merger, beneficially own (as such term is defined
in Rule 13d-3 under the Act), directly or indirectly, shares representing in the aggregate more than fifty (50) percent of the
voting shares of the Company issuing cash or securities in the consolidation or merger (or of its ultimate parent corporation,
if any), or (ii) any sale or other transfer (in one transaction or a series of transactions contemplated or arranged by any party
as a single plan) of all or substantially all of the assets of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">18.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>RESERVED</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">19.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination</U>. The Term shall continue until the termination of Executive&rsquo;s employment with the Company as provided
below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.15in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><I>Events of Termination. </I>Executive&rsquo;s employment, Base Salary and any and all other rights of Executive under this
Agreement or otherwise as an employee of the Company will terminate:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.65in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD>upon the death of Executive;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.65in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">upon the Disability of Executive (immediately upon notice from either party to the other). For purposes hereof, the term &ldquo;Disability&rdquo;
shall mean an incapacity by accident, illness or other circumstances which renders Executive mentally or physically incapable of
performing the duties and services required of Executive hereunder on a full-time basis for a period of at least 120 consecutive
days.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.65in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD>upon termination of Executive for Cause;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.65in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">upon the resignation of employment by Executive without Good Reason (upon sixty (60) days&rsquo; prior written notice);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.65in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD>upon termination by the Company for any reason other than those set forth in Sections 19(a)(i) through 19(a)(iv) above;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.65in"></TD><TD STYLE="width: 0.5in">(vi)</TD><TD>upon voluntary resignation of employment by Executive for Good Reason as described in Section 19(f), below;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.65in"></TD><TD STYLE="width: 0.5in">(vii)</TD><TD>upon a Change of Control Termination as described in Section 19(g), below.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0">Initials<U>&nbsp;&nbsp;AK&nbsp;&nbsp;</U></P></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD>&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right; font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font: italic 10pt Times New Roman, Times, Serif">Confidential</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.15in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">In the event Executive&rsquo;s termination occurs pursuant to Sections 19(a)(i) - (iv) above, Executive will be entitled only
to the Accrued Benefits through the termination date. The Company will have no further obligation to pay any compensation of any
kind (including, without limitation, any Bonus or portion of a Bonus that otherwise may have become due and payable to Executive
with respect to the year in which such termination date occurs), or severance payment of any kind, unless otherwise provided herein.
For purposes of this Agreement, Accrued Benefits shall mean (i) payment of Base Salary through the termination date, (ii) payment
of any Bonus for performance periods completed prior to the termination date, (iii) any payments or benefits under the Company&rsquo;s
benefit plans that are vested, earned or accrued prior to the termination date (including, without limitation, earned but unused
vacation); and (iv) payment of unreimbursed business expenses incurred by Executive.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.15in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">For purposes of this Agreement, &ldquo;<U>Cause</U>&rdquo; shall mean the good faith determination by the Company (which determination
shall be conclusive), after written notice from the Company to Executive that one or more of the following events has occurred
and stating with reasonable specificity the actions that constitute Cause and the specific reasonable cure (related to subsections
(i) and (viii) below):</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.65in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #080D0B">(i)</FONT></TD><TD STYLE="text-align: justify">Executive has willfully or repeatedly failed to perform Executive&rsquo;s <FONT STYLE="color: #080D0B">material duties and
such failure has not been cured after a period of thirty (30) days&rsquo; written notice;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.65in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">any reckless or grossly negligent act by Executive having the foreseeable effect of injuring the interest, business or reputation
of the Company, or any of its parents, subsidiaries or affiliates in any material respect;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.65in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">Executive&rsquo;s evidenced use of any illegal drug, or illegal narcotic, or excessive amounts of alcohol (as determined by
the Company in its reasonable discretion) on Company property or at a function where Executive is working on behalf of the Company;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.65in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">the indictment on charges or conviction for (or the procedural equivalent of conviction for), or entering of a guilty plea
or plea of no contest with respect to a felony;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.65in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">the conviction for (or the procedural equivalent of conviction for), or entering of a guilty plea or plea of no contest with
respect to a misdemeanor which, in the Company&rsquo;s reasonable judgment, involves moral turpitude deceit, dishonesty or fraud;
except that, in the event that Executive is indicted on charges for a misdemeanor set forth in this subsection 19(c)(v), the Company
may elect, in its sole discretion, to place Executive on administrative garden leave with or without continuation of full compensation
and benefits under this Agreement during the pendency of the proceedings;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0">Initials<U>&nbsp;&nbsp;AK&nbsp;&nbsp;</U></P></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD>&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right; font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font: italic 10pt Times New Roman, Times, Serif">Confidential</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.65in"></TD><TD STYLE="width: 0.5in">(vi)</TD><TD STYLE="text-align: justify">conduct by or at the direction of Executive constituting misappropriation or embezzlement of the property of the Company, or
any of its parents or affiliates (other than the occasional, customary and <I>de minimis </I>use of Company property for personal
purposes);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.65in"></TD><TD STYLE="width: 0.5in">(vii)</TD><TD STYLE="text-align: justify">a breach by Executive of a fiduciary duty owing to the Company, including the misappropriation of (or attempted misappropriation
of) a corporate opportunity or undisclosed self-dealing;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.65in"></TD><TD STYLE="width: 0.5in">(viii)</TD><TD STYLE="text-align: justify">a material breach by Executive of any material provision of this Agreement, any of the Company&rsquo;s written employment policies
or Executive&rsquo;s fiduciary duties to the Company, which breach, if curable, remains uncured for a period of thirty (30) days
after receipt by Executive of written notice of such breach from the Company, which notice shall contain a reasonably specific
description of such breach and the specific reasonable cure requested by the Supervisory Board; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.65in"></TD><TD STYLE="width: 0.5in">(ix)</TD><TD STYLE="text-align: justify">any breach of Executive&rsquo;s Confidentiality, Developments, and Restrictive Covenants Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.15in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">The definition of Cause set forth in this Agreement shall govern for purposes of Executive&rsquo;s equity compensation and
any other compensation containing such a concept.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.15in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify"><I>Notice Period for Termination Under Section 19(a)(iv). </I>Upon a termination of Executive under Section 19(a)(iv), during
the notice period the Company may, in its sole discretion, relieve Executive of all of Executive&rsquo;s duties, responsibilities,
and authority, may restrict Executive&rsquo;s access to Company property, and may take other appropriate measures deemed necessary
under the circumstances.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0">Initials<U>&nbsp;&nbsp;AK&nbsp;&nbsp;</U></P></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD>&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right; font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font: italic 10pt Times New Roman, Times, Serif">Confidential</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.15in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify"><I>Termination by Executive for Good Reason. </I>During the Term, Executive may terminate this Agreement at any time upon thirty
(30) days&rsquo; written notice to the Company for Good Reason. For purposes of this Agreement, &ldquo;<U>Good Reason</U>&rdquo;
shall mean that Executive has complied with the Good Reason Process (hereinafter defined) following the occurrence of any of the
following actions undertaken by the Company without Executive&rsquo;s express prior written consent: (i) the material diminution
in Executive&rsquo;s responsibilities, authority and function; (ii) a material reduction in Executive&rsquo;s Base Salary, provided,
however, that Good Reason shall not be deemed to have occurred in the event of a reduction in Executive&rsquo;s Base Salary which
is pursuant to a salary reduction program affecting the CEO and all or substantially all other senior management employees of the
Company and that does not adversely affect Executive to a greater extent than other similarly situated employees; provided, however
that such reduction may not exceed twenty (20%) percent; (iii) a material change in the geographic location at which Executive
provides services to the Company (i.e., outside a radius of fifty (50) miles from Lexington, Massachusetts); or (iv) a material
breach by the Company of this Agreement or any other material agreement between Executive and the Company concerning the terms
and conditions of Executive&rsquo;s employment, benefits or Executive&rsquo;s compensation (each a &ldquo;<U>Good Reason Condition</U>&rdquo;).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.15in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&ldquo;<U>Good Reason Process</U>&rdquo; shall mean
    that: (i) Executive has reasonably determined in good faith that a Good Reason Condition has occurred; (ii) Executive has
    notified the Company in writing of the first occurrence of the Good Reason Condition within 60 days of the first occurrence
    of such condition; (iii) Executive has cooperated in good faith with the Company&rsquo;s efforts, for a period not less than
    thirty (30) days following such notice (the &ldquo;<U>Cure Period</U>&rdquo;), to remedy the condition; (iv) notwithstanding
    such efforts, the Good Reason Condition continues to exist; and (v) Executive terminates employment within sixty (60) days
    after the end of the Cure Period. If the Company cures to Executive&rsquo;s satisfaction (not unreasonably withheld) the Good
    Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.15in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify"><I>Termination As A Result of a Change Of Control. </I>For purposes of this Agreement, &ldquo;<U>Change of Control Termination</U>&rdquo;
shall mean any of the following:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.65in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">Any termination by the Company of Executive&rsquo;s employment, other than for Cause (as defined in Section 19(c), above),
that occurs within twelve (12) months after the Change of Control; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.65in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">Any resignation by Executive for Good Reason (as defined in Section 19(f), above), that occurs within twelve (12) months after
the Change of Control.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.65in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">For purposes of this Section 19(g), &ldquo;Change of Control&rdquo; shall have the same meaning as defined above in Section
17.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.15in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify"><I>Separation Benefits. </I>Should Executive experience a termination of employment during the Term pursuant to Section 19(a)(v),
(vi) or (vii) above, in addition to the Accrued Benefits Executive shall also be entitled to:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0">Initials<U>&nbsp;&nbsp;AK&nbsp;&nbsp;</U></P></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD>&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right; font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font: italic 10pt Times New Roman, Times, Serif">Confidential</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.65in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD><I>Lump Sum Severance Payment</I>:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.15in; text-indent: 0.25in; text-align: justify">a.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In the case of a termination of employment during the Term pursuant to Section 19(a)(v) or (vi) above: a lump sum severance
payment equal to 100% of the sum of (A) Executive&rsquo;s annual Base Salary and (B) Executive&rsquo;s target Bonus amount pursuant
to Section 7(b) hereof (<I>i.e.</I>, 40% of Executive&rsquo;s annual Base Salary);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.15in; text-indent: 0.25in; text-align: justify">b.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In the case of a termination of employment during the Term pursuant to Section 19(a)(vii) above: a lump sum severance payment
equal to 150% of the sum of (A) Executive&rsquo;s annual Base Salary and (B) Executive&rsquo;s target Bonus amount pursuant to
Section 7(b) hereof (<I>i.e.</I>, 40% of Executive&rsquo;s annual Base Salary);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.65in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">a Pro-rata Bonus paid at the target bonus amount for the year of termination, as set forth in and subject to Section 7(b);
as used in this Agreement, the term &ldquo;<U>Pro-rata Bonus</U>&rdquo; shall mean the product of the formula B x D/365 where B
represents the target Bonus (<I>i.e.</I>, 40% of Executive&rsquo;s annual Base Salary), and D represents the number of days elapsed
in the calendar year through the date of the separation of Executive&rsquo;s employment from the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.65in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">Provided that Executive and his eligible dependents, if any, are participating in the Company&rsquo;s group health, dental
and vision plans on the termination date and elect on a timely basis to continue that participation in some or all of the offered
plans through the federal law commonly known as &ldquo;COBRA,&rdquo; the Company will pay or reimburse Executive for Executive&rsquo;s
full COBRA premiums (i.e., employer and employee portion) until the earlier to occur of: (a)&nbsp;the expiration of the COBRA Payment
Term (as defined below), (b)&nbsp;the date Executive becomes eligible to enroll in the health, dental and/or vision plans of another
employer, (c)&nbsp;the date Executive (and/or his eligible dependents, as applicable) is no longer eligible for COBRA coverage,
or (d)&nbsp;the Company in good faith determines that payments under this paragraph would result in a discriminatory health plan
pursuant to the Patient Protection and Affordable Care Act of 2010, as amended, and any guidance or regulations promulgated thereunder
(collectively, &ldquo;<U>PPACA</U>&rdquo;). Executive agrees to notify the Company promptly if he becomes eligible to enroll in
the plans of another employer or if he or any of his dependents cease to be eligible to continue participation in the Company&rsquo;s
plans through COBRA. &ldquo;COBRA Payment Term&rdquo; mean (x) in the case of a termination of employment during the Term pursuant
to Section 19(a)(v) or (vi) above, the twelve (12) month anniversary of Executive&rsquo;s termination date, and (y) in the case
of a termination of employment during the Term pursuant to Section 19(a)(vii) above, the eighteen (18) month anniversary of Executive&rsquo;s
termination date.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0">Initials<U>&nbsp;&nbsp;AK&nbsp;&nbsp;</U></P></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD>&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right; font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font: italic 10pt Times New Roman, Times, Serif">Confidential</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.65in; text-indent: 0in; text-align: justify">To avoid duplication of severance
payments, any amount paid under this subsection shall be offset against any severance amounts that may be owed by the Company to
Executive pursuant to any of Company&rsquo;s Change of Control guidelines as may be adopted or amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">20.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>General Release of Claims</U>. Notwithstanding any provision of this agreement, all severance payments and benefits described
in Section 19 of this Agreement (except for payment of the Accrued Benefits) are conditioned upon the execution, delivery to the
Company, and expiration of any applicable revocation period without a notice of revocation having been given by Executive, all
by the 30th day following the termination date of a General Release of Claims by and between Executive (or Executive&rsquo;s estate)
and the Company in the form attached as <U>Exhibit B</U> to this Agreement. (In the event of Executive&rsquo;s death or incapacity
due to Disability, the release will be revised for signature accordingly.) Provided any applicable timing requirements set forth
above have been met, the payments and benefits will be paid or provided to Executive as soon as administratively practicable (but
not later than forty-five (45) days) following the date Executive signs and delivers the General Release to the Company and any
applicable revocation period has expired without a notice of revocation having been given. Any severance or termination pay will
be the sole and exclusive remedy, compensation or benefit due to Executive or Executive&rsquo;s estate upon any termination of
Executive&rsquo;s employment (without limiting Executive&rsquo;s tights under any disability, life insurance, or deferred compensation
arrangement in which Executive participates or at the time of such termination of employment or any Option Agreements or any other
equity agreements to which Executive is a party).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="color: #070C0B">21.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><U>Certain Company Remedies</U>. Executive acknowledges that Executive&rsquo;s promised services and covenants are
of a special and unique character, which give them peculiar value, the loss of which cannot be reasonably or adequately compensated
for in an action at law, and that, in the event there is a breach hereof by Executive, the Company will suffer irreparable harm,
the amount of which will be impossible to ascertain. Accordingly, the Company shall be entitled, if it so elects, to institute
and prosecute proceedings in any court of competent jurisdiction, either at <FONT STYLE="color: #070C0B">law or in equity, to obtain
damages for any breach of this Agreement, or to enjoin Executive from committing any act in breach of this Agreement. The remedies
granted to the Company in this Agreement are cumulative and are in addition to remedies otherwise available to the Company at law
or in equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">22.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Indemnification</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.15in; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify">(a)</TD><TD STYLE="text-align: justify">The Company agrees that Executive shall be entitled to indemnification to the fullest extent permitted by Delaware law and
under the Company&rsquo;s articles of incorporation, bylaws and any other corporate-related plan, program or policy. In addition,
for a period of at least three (3) years after Executive&rsquo;s termination of employment, the Company shall maintain a directors
and officers liability insurance policy under which Executive shall be included as a &ldquo;Covered Person.&rdquo;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0">Initials<U>&nbsp;&nbsp;AK&nbsp;&nbsp;</U></P></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD>&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right; font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font: italic 10pt Times New Roman, Times, Serif">Confidential</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.15in; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="color: #070C0B">(b)</FONT></TD><TD STYLE="text-align: justify">In addition, and for the sake of clarity, the Company hereby specifically agrees that (i) if
Executive is made a party, or is threatened to be made a party, to any &ldquo;<U>Proceeding</U>&rdquo; (defined as any threatened
or actual action, suit or proceeding whether civil, criminal, administrative, investigative, appellate or other) by reason of the
fact that (1) Executive is or was an employee, officer, director, agent, consultant or representative of the Company, or (2) is
or was serving at the request of the Company as employee, officer, director, agent, consultant or <FONT STYLE="color: #070C0B">representative
of another person, or (ii) if any &ldquo;<U>Claim</U>&rdquo; (defined as any claim, demand, request, investigation, dispute, controversy,
threat, discovery request or request for testimony or information) is made, or threatened to be made, that arises out of or relates
to Executive&rsquo;s service in any of the foregoing capacity or to the Company, then Executive shall be indemnified and held harmless
by the Company to the fullest extent permitted by applicable law, against any and all costs, expenses, liabilities and losses (including,
without limitation, attorney&rsquo;s fees, judgments, interest, expenses of investigation, penalties, fines, taxes or penalties
and amounts paid or to be paid in settlement) incurred or suffered by </FONT>Executive in connection therewith, except with respect
to any costs, expenses, liabilities or losses (A) that were incurred of suffered as a result of Executive&rsquo;s willful misconduct,
gross negligence or knowing violation of any written agreement between Executive and the Company, (B) that a court of competent
jurisdiction determines to have resulted from <FONT STYLE="color: #070C0B">Executive&rsquo;s knowing and fraudulent acts; provided,
however, that the Company shall provide such indemnification only if (I) notice of any such Proceeding is given promptly to the
Company, by Executive; (II) the Company is permitted to participate in and assume the defense of any such Proceeding; (III) such
cost, expense, liability or loss results from the final judgment of a court of competent jurisdiction or as a result of a settlement
entered into with the prior written consent of the Company; and (IV) in the case of any such Proceeding (or part thereof) initiated
by Executive, such Proceeding (or part thereof) was authorized in advance in writing by the Company. Such indemnification shall
continue even if Executive has ceased to be an employee, officer, director, agent, consultant or representative of the Company
until all applicable statute of limitations have expired, and shall inure to the benefit of Executive&rsquo;s heirs, executors
and administrators. The Company shall pay directly or advance to Executive all costs and expenses incurred by Executive in connection
with any such Proceeding or Claim (except for Proceedings brought by the Company against Executive for claims other than shareholder
derivative actions) within 30 days after receiving written notice requesting such an advance. Such notice shall include, to the
extent required by applicable law, an undertaking by Executive to repay the amount advanced if Executive was ultimately determined
not to be entitled to indemnification against such costs and expenses</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">23.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.15in; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify">(a)</TD><TD STYLE="text-align: justify"><I>Right to Offset. </I>The Company may offset any undisputed amounts Executive owes the Company at the time of Executive&rsquo;s
termination of employment (including any payment of Accrued Benefits or separation pay), except for secured or unsecured loans,
against any amounts the Company owes Executive hereunder, subject in all cases to the requirements of Section 409A of the Code.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0">Initials<U>&nbsp;&nbsp;AK&nbsp;&nbsp;</U></P></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD>&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right; font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font: italic 10pt Times New Roman, Times, Serif">Confidential</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.15in; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify">(b)</TD><TD STYLE="text-align: justify"><I>Cooperation. </I>Executive agrees that, during and after Executive&rsquo;s employment with the Company, subject to reimbursement
of Executive&rsquo;s reasonable expenses, Executive will cooperate fully with the Company and its counsel with respect to any matter
(including, without limitation, litigation, investigations, or governmental proceedings) in which Executive was in any way involved
during Executive&rsquo;s employment with the Company. Executive shall render such cooperation in a timely manner on reasonable
notice from the Company, and at such times and places as reasonably acceptable to Executive and the Company. The Company, following
Executive&rsquo;s termination of employment, exercises commercially reasonable efforts to schedule and limit its need for Executive&rsquo;s
cooperation under this paragraph so as not to interfere with Executive&rsquo;s other personal and professional commitments.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.15in; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="color: #080C0B">(c)</FONT></TD><TD STYLE="text-align: justify"><I>Company Documents and Property. </I>Upon termination of Executive&rsquo;s employment with
the Company, or at any other time upon the request of Company, Executive shall forthwith deliver to Company any and all documents,
notes, notebooks, letters, manuals, prints, drawings, block diagrams, photocopies of documents, devices, equipment, keys, security
passes, credit cards, hardware, data, databases, source code, object code, and data or computer programming code stored on an optical
or electronic medium, and any copies thereof, in the possession of or under the control of Executive that embodies any confidential
information of the Company. Executive agrees to refrain from purging or deleting data from any <FONT STYLE="color: #080C0B">Company-owned
equipment, including email systems, in connection with Executive&rsquo;s termination. To the extent that Executive possesses any
data belonging to Company on any storage media owned by Executive (for example, a home computer&rsquo;s hard disk drive, portable
data storage device, etc.), Executive agrees that Executive will work cooperatively with the Company to return such data and ensure
it is removed from Executive&rsquo;s devices in a manner that does not adversely impact any personal data. Executive agrees not
to take any steps to delete any Company data from any device without first obtaining Company&rsquo;s written approval. Executive
agrees to cooperate with Company if Company requests written or other positive confirmation of the return or destruction of such
data from any personal storage media. Nothing herein shall be deemed to prohibit Executive from retaining (and making copies of):
Executive&rsquo;s personal non-business-related correspondence files; or (ii) documents relating to Executive&rsquo;s personal
compensation, benefits, and obligations.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.15in; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify">(d)</TD><TD STYLE="text-align: justify"><I>Waivers. </I>No waiver of any provision will be effective unless made in writing and signed by the waiving party. The failure
of any party to require the performance of any term or obligation of this Agreement does not prevent subsequent enforcement of
that term or obligation. The waiver by any party of any breach of this Agreement does not waive any subsequent breach.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0">Initials<U>&nbsp;&nbsp;AK&nbsp;&nbsp;</U></P></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD>&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right; font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font: italic 10pt Times New Roman, Times, Serif">Confidential</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.15in; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify">(e)</TD><TD STYLE="text-align: justify"><I>Section 409A</I>. This Agreement is intended to comply with Section 409A of the Code, and its corresponding regulations,
or an exemption thereto, and payments may only be made under this Agreement upon an event and in a manner permitted by Section
409A of the Code, to the extent applicable. Severance benefits under this Agreement are intended to be exempt from Section 409A
of the Code under the &ldquo;short-term deferral&rdquo; exception, to the maximum extent applicable, and then under the &ldquo;separation
pay&rdquo; exception, to the maximum extent applicable. Notwithstanding anything in this Agreement to the contrary, if required
by Section 409A of the Code, if Executive is considered a &ldquo;specified employee&rdquo; for purposes of Section 409A of the
Code and if payment of any amounts under this Agreement is required to be delayed for a period of six months after separation from
service pursuant to Section 409A of the Code, payment of such amounts shall be delayed as required by Section 409A of the Code,
and the accumulated amounts shall be paid in a lump-sum payment within 10 days after the end of the six-month period. If Executive
dies during the postponement period prior to the payment of benefits, the amounts withheld on account of Section 409A of the Code
shall be paid to the personal representative of Executive&rsquo;s estate within 60 days after the date of Executive&rsquo;s death.
All payments to be made upon a termination of employment under this Agreement may only be made upon a &ldquo;separation from service&rdquo;
under Section 409A of the Code. For purposes of Section 409A of the Code, each payment hereunder shall be treated as a separate
payment, and the right to a series of installment payments under this Agreement shall be treated as a right to a series of separate
payments. In no event may Executive, directly or indirectly, designate the fiscal year of a payment. Notwithstanding any provision
of this Agreement to the contrary, in no event shall the timing of Executive&rsquo;s execution of the General Release, directly
or indirectly, result in Executive&rsquo;s designating the fiscal year of payment of any amounts of deferred compensation subject
to Section 409A of the Code, and if a payment that is subject to execution of the General Release could be made in more than one
taxable year, payment shall be made in the later taxable year. All reimbursements and in-kind benefits provided under this Agreement
shall be made or provided in accordance with the requirements of Section 409A of the Code, including, where applicable, the requirement
that (i) any reimbursement be for expenses incurred during the period specified in this Agreement, (ii) the amount of expenses
eligible for reimbursement, or in-kind benefits provided, during a fiscal year not affect the expenses eligible for reimbursement,
or in-kind benefits to be provided, in any other fiscal year, (iii) the reimbursement of an eligible expense be made no later than
the last day of the fiscal year following the year in which the expense is incurred, and (iv) the right to reimbursement or in-kind
benefits not be subject to liquidation or exchange for another benefit.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0">Initials<U>&nbsp;&nbsp;AK&nbsp;&nbsp;</U></P></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD>&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right; font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font: italic 10pt Times New Roman, Times, Serif">Confidential</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.15in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify"><I>Governing Law; Consent to Exclusive Jurisdiction and Venue. </I>This Agreement and all questions relating to its validity,
interpretation, performance and enforcement (including, without limitation, provisions concerning limitations of actions), shall
be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts (notwithstanding any conflict-of-laws
doctrines of such state or other jurisdiction to the contrary), and without the aid of any canon, custom or rule of law requiring
construction against the draftsman. The parties hereby consent and submit to the exclusive jurisdiction of the federal and state
courts in the Commonwealth of Massachusetts, and to exclusive venue in any Massachusetts federal court and/or Massachusetts state
court located in Suffolk County, for any dispute arising from this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.15in; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify">(g)</TD><TD STYLE="text-align: justify"><I>Notices. </I>Any notices, requests, demands, and other communications described in this Agreement are sufficient if in writing
and delivered in person or sent postage prepaid, by certified or registered U.S. mail or by FedEx/UPS <B>to </B>Executive at Executive&rsquo;s
last known home address and a copy by e-mail to Executive, or in the case of the Company, to the attention of the CFO or SVP HR,
copy to the CEO at the main office of uniQure, N.V. Any notice sent by U.S. mail shall be deemed given for all purposes 72 hours
from its deposit in the U.S. mail, or the next day if sent by overnight delivery.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.15in; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify">(h)</TD><TD STYLE="text-align: justify"><I>Successors and Assigns. </I>Executive may not assign this Agreement, by operation of law or otherwise, without the Company&rsquo;s
prior written consent. Without the Company&rsquo;s consent, any attempted transfer or assignment will be void and of no effect.
The Company may assign its rights under this Agreement if the Company consolidates with or merges into any other entity, or transfers
substantially all of its properties or assets to any other entity, provided that such entity expressly agrees to be bound by the
provisions hereof. This Agreement will inure to the benefit of and be binding upon the Company and Executive, their respective
successors, executors, administrators, heirs, and permitted assigns.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.15in; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify">(i)</TD><TD STYLE="text-align: justify"><I>Counterparts; Facsimile. </I>This Agreement may be executed in two or more counterparts, each of which shall be an original
and all of which together shall constitute one and the same instrument. This Agreement may be executed by facsimile transmission,
PDF, electronic signature or other similar electronic means with the same force and effect as if such signature page were an original
thereof.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.15in; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify">(j)</TD><TD STYLE="text-align: justify"><I>Severability. </I>The provisions of this Agreement are independent of and separable from each other, and no provision shall
be affected or rendered invalid or unenforceable by virtue of the fact that for any reason any other provision or provisions may
be invalid or unenforceable in whole or in part.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0">Initials<U>&nbsp;&nbsp;AK&nbsp;&nbsp;</U></P></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD>&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right; font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font: italic 10pt Times New Roman, Times, Serif">Confidential</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.15in; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify">(k)</TD><TD STYLE="text-align: justify"><I>Enforceability. </I>If any portion or provision of the Agreement is declared illegal or unenforceable by a court of competent
jurisdiction, the remainder of the Agreement will not be affected, and each remaining portion and provision of this Agreement will
be valid and enforceable to the fullest extent permitted by law.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.15in; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify">(l)</TD><TD STYLE="text-align: justify"><I>Survival. </I>Sections 13, 20, 21, and the Company&rsquo;s Confidentiality, Developments, and Restrictive Covenants Agreement
(<U>Exhibit A</U>) and all other provisions necessary to give effect thereto, shall survive the termination of Executive&rsquo;s
employment for any reason.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.15in; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify">(m)</TD><TD STYLE="text-align: justify"><I>Recoupment and Other Policies.</I> All payments under this Agreement shall be subject to any applicable clawback and recoupment
policies and other policies that may be implemented by the Board from time to time, including, without limitation, the Company&rsquo;s
right to recover amounts in the event of a financial restatement due in whole or in part to fraud or misconduct by one or more
of the Company&rsquo;s executives or in the event Executive violates any applicable restrictive covenants in favor of the Company
to which Executive is subject.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.15in; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify">(n)</TD><TD STYLE="text-align: justify"><I>Entire Agreement; Amendment. </I>This Agreement contains the entire understanding among the parties hereto with respect
to the subject matter hereof, and supersedes all prior and contemporaneous agreements and understandings, inducements or conditions,
express or implied, oral or written, between the parties hereto (including without limitation any prior employment agreements between
the parties hereto); provided, however, that any agreements referenced in this Agreement or executed herewith are not superseded.
The express terms hereof control and supersede any course of performance and/or usage of the trade inconsistent with any of the
terms hereof. This Agreement may be amended or modified only by a written instrument signed by Executive and by a duly authorized
representative of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.15in; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify">(o)</TD><TD STYLE="text-align: justify"><I>Section Headings. </I>The section headings in this Agreement are for convenience only, form no part of this Agreement and
shall not affect its interpretation.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[This space intentionally left blank.]</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0">Initials<U>&nbsp;&nbsp;AK&nbsp;&nbsp;</U></P></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD>&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right; font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font: italic 10pt Times New Roman, Times, Serif">Confidential</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the parties have executed
and delivered this Agreement as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">uniQure,
    Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">/s/ Matthew Kapusta<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    Matthew Kapusta</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXECUTIVE</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">/s/ <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Alex
    Kuta</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alex
    Kuta</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0">Initials<U>&nbsp;&nbsp;AK&nbsp;&nbsp;</U></P></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD>&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right; font: italic 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Split-Segment; Name: 2 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">EXHIBIT A<BR>
UNIQURE, INC.<BR>
CONFIDENTIALITY, DEVELOPMENTS, AND<BR>
RESTRICTIVE COVENANTS AGREEMENT<BR>
[ attached ]</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 18; Options: NewSection; Value: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Confidentiality, Development and </I></P><P STYLE="margin: 0pt 0"><I>Restrictive Covenant Agreement</I></P></TD><TD STYLE="width: 34%; text-align: center; vertical-align: bottom">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right; vertical-align: bottom"><P STYLE="margin: 0pt 0"><I>Employee Initials</I> ____</P></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD>&nbsp;</TD><TD STYLE="text-align: center"></TD><TD STYLE="text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>EXHIBIT B</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>GENERAL RELEASE OF CLAIMS</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt; text-indent: 0.5in">In exchange for the promises and benefits
set forth in Section 19 of the Employment Agreement between uniQure, Inc. and <B>Alex Kuta </B>made as of <B>August 20, 2019, </B>and
to be provided to me following the Effective Date of this General Release, I, <B>Alex Kuta, </B>on behalf of myself, my heirs,
executors and assigns, hereby acknowledge, understand and agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
behalf of myself and my family, heirs, executors, administrators, personal representatives, agents, employees, assigns, legal representatives,
accountants, affiliates and for any partnerships, corporations, sole proprietorships, or other entities owned or controlled by
me, I fully release, acquit, and forever discharge uniQure, Inc., its past, present and future officers, directors, shareholders,
agents, representatives, insurers, employees, attorneys, subsidiaries, affiliated corporations, parents, and assigns (collectively,
the &ldquo;Releasees&rdquo;), from any and all charges, actions, causes of action, claims, grievances, damages, obligations, suits,
agreements, costs, expenses, attorneys&rsquo; fees, or any other liability of any kind whatsoever, suspected or unsuspected, known
or unknown, which have or could have arisen out of my employment with or services performed for Releasees and/or termination of
my employment with or termination of my services performed for Releasees (collectively, &ldquo;Claims&rdquo;), including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">a.</TD><TD STYLE="text-align: justify">Claims arising under Title VII of the Civil Rights Act of 1964 (as amended); the Civil Rights Acts
of 1866 and 1991; the Americans With Disabilities Act; the Family and Medical Leave Act; the Employee Retirement Income Security
Act; the Occupational Health and Safety Act; the Sarbanes-Oxley Act; the Massachusetts Law Against Discrimination (M.G.L. c. 151B,
et seq., and/or any other laws of the Commonwealth of Massachusetts related to employment or the separation from employment;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">b.</TD><TD STYLE="text-align: justify">Claims for age discrimination arising under the Age Discrimination in Employment Act of 1967 (as
amended) (&ldquo;ADEA&rdquo;) and the Older Workers Benefits Protection Act, except ADEA claims that may arise after the execution
of this General Release;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">c.</TD><TD STYLE="text-align: justify">Claims arising out of any other federal, state, local or municipal statute, law, constitution,
ordinance or regulation; and/or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">d.</TD><TD STYLE="text-align: justify">Any other employment related claim whatsoever, whether in contract, tort or any other legal theory,
arising out of or relating to my employment with the Company and/or my separation of employment from the Releasees.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">e.</TD><TD STYLE="text-align: justify">Excluded from this General Release are any claims that cannot be released or waived by law. This
includes, but is not limited to, my right to file a charge with or participate in an investigation conducted by certain government
agencies, such as the EEOC or NLRB. I acknowledge and agree, however, that I am releasing and waiving my right to any monetary
recovery should any government agency pursue any claims on my behalf that arose prior to the effective date of this General Release.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">f.</TD><TD STYLE="text-align: justify">I waive all rights to re-employment with the Releasees. If I do apply for employment with the Releasees,
the Releasees and I agree that the Releasees need not employ me, and that if the Releasees declines to employ me for any reason,
it shall not be liable to me for any cause of action or damages whatsoever.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 19; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>General Release of Claims</I></P></TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right; vertical-align: bottom"><P STYLE="margin: 0pt 0"><I>Employee Initials</I> ____</P></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD>&nbsp;</TD><TD STYLE="text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right; font: italic 10pt Times New Roman, Times, Serif">Confidential&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Release
of Other Claims. I fully release, acquit, and forever discharge the Releasees from any and all other charges, actions, causes of
action, claims, grievances, damages, obligations, suits, agreements, costs, expenses, attorneys&rsquo; fees or any other liability
of any kind whatsoever of which I have knowledge as of the time I sign this General Release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I
further acknowledge that I have received payment, salary and wages in full for all services rendered in conjunction with my employment
with uniQure, Inc., including payment for all wages, bonuses, and accrued, unused paid time off, and that no other compensation
is owed to me except as provided herein. I specifically understand that this general release of claims includes, without limitation,
a release of claims for alleged wages due, overtime or other compensation or payment including any claim for treble damages, attorneys&rsquo;
fees and costs pursuant to the Massachusetts Wage Act and State Overtime Law M.G.L. c. 149, &sect;&sect;148, 150 <I>et seq. </I>and
M.G.L. c. 151, &sect;IA <I>et seq. </I>and I further acknowledge that I are unaware of any facts that would support a claim against
the Released Parties for violation of the Fair Labor Standards Act or the Massachusetts Wage Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
anything to the contrary herein, nothing in this General Release shall be deemed to release any of the Releasees for: (i) any claim
for the payment of compensation due under the Employment Agreement; (ii) any claim for any of the Accrued Benefits under the Employment
Agreement; (iii) any claim for any separation benefit under Section 19 of the Employment Agreement including, without limitation,
separation pay and accelerated vesting of stock options (as applicable and as defined in the Employment Agreement); or (iv) any
rights to indemnification or coverage under a directors and officers liability insurance policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restrictive
Covenants. I acknowledge and agree that all of my obligations under the restrictive covenants in my Confidentiality, Developments,
and Restrictive Covenants Agreement remain in full force and effect and shall survive the termination of my employment with the
Releasees and the execution of this General Release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consultation
with Attorney. I am advised and encouraged to consult with an attorney prior to executing this General Release. I acknowledge that
if I have executed this General Release without consulting an attorney, I have done so knowingly and voluntarily.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Period
for Review. I acknowledge that I have been given at least 21 days from the date I first received this General Release (or at least
45 days from the date I first received this General Release if my termination is part of a group reduction in force) during which
to consider signing it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revocation
of General Release. I acknowledge and agree that I have the right to revoke my acceptance of this General Release if I notify the
Releasees in writing within 7 calendar days following the date I sign it. Any revocation, to be effective, must be in writing,
signed by me, and either: a) postmarked within 7 calendar days of the date I signed it and addressed to the then current address
of uniQure, Inc.&rsquo;s headquarters (to the attention of the CEO); orb) hand delivered within 7 days of execution of this General
Release to the uniQure, Inc.&rsquo;s CEO. This General <FONT STYLE="color: #080B0A">Release will become effective on the 8th day
after I sign it (the &ldquo;Effective Date&rdquo;); provided that I have not timely revoked it.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Confidentiality, Development and </I></P><P STYLE="margin: 0pt 0"><I>Restrictive Covenant Agreement</I></P></TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right; vertical-align: bottom"><P STYLE="margin: 0pt 0"><I>Employee Initials</I> ____</P></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD>&nbsp;</TD><TD STYLE="text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; text-align: right; font: italic 10pt Times New Roman, Times, Serif"><I STYLE="font: italic 10pt Times New Roman, Times, Serif">Confidential</I></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">I ACKNOWLEDGE AND AGREE THAT I HAVE BEEN
ADVISED THAT THE GENERAL RELEASE IS A LEGAL DOCUMENT, AND I HAVE BEEN ADVISED TO CONSULT WITH AN ATTORNEY CONCERNING THIS GENERAL
RELEASE. I ACKNOWLEDGE AND AGREE THAT I HAVE CAREFULLY READ AND FULLY UNDERSTAND ALL PROVISIONS OF THIS GENERAL RELEASE AND I AM
VOLUNTARILY AND KNOWINGLY SIGNING IT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN, WITNESS WHEREOF, I have duly executed
this Agreement under seal as of the ________ <FONT STYLE="color: #080B0A">[day] of _______ [month],</FONT><FONT STYLE="color: #31448E">_________
</FONT><FONT STYLE="color: #080B0A">[year]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">Alex Kuta</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">293 Willis Road, Sudbury, MA 01776</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 21; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Confidentiality, Development and </I></P><P STYLE="margin: 0pt 0"><I>Restrictive Covenant Agreement</I></P></TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right; vertical-align: bottom"><P STYLE="margin: 0pt 0"><I>Employee Initials</I> ____</P></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD>&nbsp;</TD><TD STYLE="text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>tv529829_ex10-2.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="tv529829_ex10-2img01.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 50%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; text-align: center; border-top: Black 1pt solid">employment
    AGREEMENT PURSUANT TO</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="1" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: none; text-align: center">SECTION
    7:610 (et seq.) of the Dutch Civil</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="1" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Code
    (DCC)</TD></TR>
</TABLE>




<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">August 20, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Employment agreement between</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">(1)</TD><TD STYLE="text-align: justify"><B>uniQure
                                         biopharma B.V.,</B> a company with limited liability (<I>besloten vennootschap met beperkte
                                         aansprakelijkheid)</I>, with registered office at Amsterdam and principal place of business
                                         at Paasheuvelweg 25a, (1105 BP) Amsterdam (the <B>Employer</B>); and</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">(2)</TD><TD STYLE="text-align: justify"><B>Sander
                                         van Deventer</B> born on November 1, 1954 (the <B>Employee</B>);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.6in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">each &ldquo;a Party&rdquo;, collectively, &ldquo;the Parties&rdquo;.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify"><B>1</B></TD><TD STYLE="text-align: justify"><B>Commencement
                                         date Agreement and position</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">1.1</TD><TD STYLE="text-align: justify">On
                                         August 20, 2019 (the &ldquo;Effective Date&rdquo;), this employment agreement (the &ldquo;Agreement&rdquo;)
                                         will become effective and Employee shall continue his employment with Employer in a new
                                         role, assuming a part-time (80%), 0.8 FTE, position with the Employer in the position
                                         of Executive Vice President, Research and Product Development. Employee undertakes to
                                         perform all the activities as set out in Exhibit A (Job Description) and that can reasonably
                                         be assigned to him by or on behalf of the Employer and which are related to the Employer's
                                         business. To the best of his ability in doing so, the Employee will comply with the instructions
                                         given to him by or on behalf of the Employer.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-indent: -45pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">1.2</TD><TD STYLE="text-align: justify">This
                                         Agreement replaces and supersedes the prior Employment Agreement dated August 4, 2017,
                                         which is contemporaneously terminated as of the Effective Date of this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">1.3</TD><TD STYLE="text-align: justify">The
                                         Employer shall be entitled to assign other duties than the usual activities of the Employee,
                                         or to alter the position of the Employee if in the reasonable opinion of the Employer
                                         the business circumstances so require.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.15pt; text-align: justify; text-indent: -38.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">1.4</TD><TD STYLE="text-align: justify">The
                                         Employee shall not be engaged in any business activity which, in the judgment of the
                                         Employer, conflicts with Employee&rsquo;s ability to carry out his duties for the Employer,
                                         whether or not such activity is pursued for pecuniary advantage, without the approval
                                         of the Board of Directors of uniQure N.V (the &ldquo;Board&rdquo;), other than business
                                         activities undertaken in his capacity as a general partner or venture partner of Forbion
                                         Capital Partners or its affiliated funds for up to 20% of his time. It is the mutual
                                         understanding that the Employee has resigned as Managing Partner of Forbion Capital Partners,
                                         it being understood that the Employee will thereafter continue as a venture partner or
                                         similar function with Forbion Capital Partners or its affiliated funds for up to 20%
                                         of his time.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">1.5</TD><TD STYLE="text-align: justify">The
                                         work will be performed at the office of the Employer at Paasheuvelweg 25a (1105 BP) in
                                         Amsterdam provided, however, that the Employee shall be required to travel from time
                                         to time for business purposes. The Employer reserves the right to change the location
                                         where the work is performed after consultation with the Employee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">1.6</TD><TD STYLE="text-align: justify">The
                                         normal working hours for a full-time, 1.0 FTE position are 40 hours per week. The working
                                         hours are normally 8.5 hours a day with a thirty (30) minute lunch break.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.45pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.45pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paasheuvelweg 25a</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chamber of Commerce:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="width: 23%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">P.O. Box 22506</FONT></TD><TD STYLE="width: 25%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34275365</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1100 DA Amsterdam, NL</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">legal entity: uniQure biopharma B.V.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">T: +31 20 240 6000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">www.uniQure.com</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F: +31 20 240 6020</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">info@uniQure.com</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><IMG SRC="tv529829_ex10-2img01.jpg" ALT="">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.45pt 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.65in; text-align: justify">2</TD><TD STYLE="text-align: justify">Term
                                         and termination Agreement</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">2.1</TD><TD STYLE="text-align: justify">The
                                         Agreement has been entered into for an indefinite period of time.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">2.2</TD><TD STYLE="text-align: justify">The
                                         Agreement will in any event, without notice being required, terminate as of the first
                                         day of the month following the date the Employee reaches the State pension age (AOW-gerechtigde
                                         leeftijd).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">2.3</TD><TD STYLE="text-align: justify">The
                                         Agreement can be terminated by each of the Parties with due observance of the statutory
                                         notice period of 4 months for the Employer and 2 months for the Employee.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">2.4</TD><TD STYLE="text-align: justify; padding-right: 9.3pt">Severance
                                         Payments.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">2.4.1</TD><TD STYLE="text-align: justify">lf
                                         the Agreement is terminated on the initiative of Employer, other than in the case of
                                         summary dismissal as referred to in article 7:677 of the Dutch Civil Code, long-term
                                         illness (article 7:669 section 3 under b Dutch Civil Code) or severely culpable acts
                                         or omissions by Employee as referred to in article 7:669 section 3 under the Dutch Civil
                                         Code, Employer shall grant the Employee severance pay equal to 100% of (i) the annual
                                         prorated base salary excluding 8% holiday allowance, plus (ii) the amount of the Target
                                         Bonus (<I>i.e.</I>, 40% of the annual Pro-rata Base Salary (as defined in Clause 3)),
                                         excluding holiday allowance, (hereinafter: 'Severance Pay') subject to deductions that
                                         are authorized by Employee and/or required by applicable laws and regulations.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">2.4.2</TD><TD STYLE="text-align: justify">lf
                                         the Agreement is terminated on the initiative of Employer within twelve (12) months of
                                         a Change of Control (as defined below), other than in the case of summary dismissal as
                                         referred to in article 7:677 of the Dutch Civil Code, long-term illness (article 7:669
                                         section 3 under b Dutch Civil Code) or severely culpable acts or omissions by Employee
                                         as referred to in article 7:669 section 3 under the Dutch Civil Code, claus 2.4.1 shall
                                         not apply and, instead, Employer shall grant the Employee severance pay equal to 150%
                                         of (i) the annual prorated base salary excluding 8% holiday allowance, plus (ii) the
                                         amount of the Target Bonus (<I>i.e.</I>, 40% of the annual Pro-rata Base Salary), excluding
                                         holiday allowance, (hereinafter: 'Severance Pay on a Change of Control') subject to deductions
                                         that are authorized by Employee and/or required by applicable laws and regulations. Employer
                                         shall not owe any payments or partial payments of any kind under both clauses 2.4.1 and
                                         2.4.2, which are mutually exclusive.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">2.4.3</TD><TD STYLE="text-align: justify">If
                                         Severance Pay under clause 2.4.1 or Severance Pay on a Change of Control under clause
                                         2.4.2 is owed to the Employee, then the Employer shal grant the Employee additional severance
                                         pay equal to a prorated Target Bonus amount for the year of termination as provided in
                                         this clause (the &ldquo;Pro-rata Bonus&rdquo;). The Pro-rata Bonus shall be the product
                                         of the formula B x D/365 where B represents the Target Bonus (<I>i.e.</I>, 40% of the
                                         annual Pro-rata Base Salary)), and D represents the number of days elapsed in the calendar
                                         year through the date of the separation of Executive&rsquo;s employment from the Employer.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">2.4.4</TD><TD STYLE="text-align: justify">lf
                                         and insofar as Employee is entitled to the transition payment as referred to in article
                                         7:673 of the Dutch Civil Code, this transition payment shall be deemed to be factored
                                         into the Severance pay, the Severand pay on a Change of Control, and the Pro-Rata Bonus.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paasheuvelweg 25a</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chamber of Commerce:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="width: 23%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">P.O. Box 22506</FONT></TD><TD STYLE="width: 25%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34275365</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1100 DA Amsterdam, NL</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">legal entity: uniQure biopharma B.V.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">T: +31 20 240 6000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">www.uniQure.com</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F: +31 20 240 6020</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">info@uniQure.com</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><IMG SRC="tv529829_ex10-2img01.jpg" ALT="">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">2.4.5</TD><TD STYLE="text-align: justify">In
                                         the event of a termination under this clause 2.4, the Employer shall provide 4 months'
                                         notice to the Employee. The Employer, in its sole discretion subject to applicable law,
                                         may choose to put the Employee on garden leave at any time during the notice period.
                                         Garden leave will be consldered equal to continuation of full time employment, but the
                                         Employee will be released trom his working duties. In the event that the Employee is
                                         placed on garden leave, the amount of the severance pay under this clause 2.4 will be
                                         reduced by an amount equivalent to the salary during the Employee's garden leave, and
                                         the effective date of the garden leave shall be the the date of the separation of Executive&rsquo;s
                                         employment from the Employer for purposes of calculating the Pro-rata Bonus of clause
                                         2.4.3.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">2.4.6</TD><TD STYLE="text-align: justify">In
                                         the event of a Change of Control as defined below, the vesting conditions that may apply
                                         to any stock options, restricted shares, restricted stock units, performance stock units
                                         or other grants of equity held by Executive pursuant to this Agreement and the Company&rsquo;s
                                         Amended and Restated 2014 Share Incentive Plan will be automatically waived and shall
                                         be deemed fully vested immediately prior to the Change of Control event. All Stock Options
                                         will be deeed to be fully exercisable commencing on the date of and immediately prior
                                         to the Change of Control and ending on the eighteen (18) month anniversary of the Change
                                         of Control or, if earlier, the expiration of the term of such Stock Options.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">2.4.7</TD><TD STYLE="text-align: justify; padding-right: 9.3pt">For
                                         purposes of this Agreement, &ldquo;Change of Control&rdquo; shall mean the date on which
                                         any of the following events occurs:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">2.4.7.1</TD><TD STYLE="text-align: justify">any
                                         &ldquo;person,&rdquo; as such term is used in Sections 13(d) and 14(d) of the United
                                         States Securities Exchange Act of 1934, as amended (the &ldquo;Act&rdquo;) (other than
                                         uniQure N.V. (the &ldquo;Company&rdquo;), any of its subsidiaries, or any trustee, fiduciary
                                         or other person or entity holding securities under any employee benefit plan or trust
                                         of the Company or any of its subsidiaries), together with all &ldquo;affiliates&rdquo;
                                         and &ldquo;associates&rdquo; (as such terms are defined in Rule 12b-2 under the Act)
                                         of such person, shall become the &ldquo;beneficial owner&rdquo; (as such term is defined
                                         in Rule 13d-3 under the Act), directly or indirectly, of securities of the Company representing
                                         forty (40) percent or more of the combined voting power of the Company&rsquo;s then outstanding
                                         securities having the right to vote in an election of the Board (&ldquo;Voting Securities&rdquo;)
                                         (in such case other than as a result of an acquisition of securities directly from the
                                         Company); or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">2.4.7.2</TD><TD STYLE="text-align: justify">a
                                         majority of the members of the Board is replaced during any 12-month period by directors
                                         whose appointment or election is not endorsed by a majority of the members of the Board
                                         before the date of the appointment or election; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">2.4.7.3</TD><TD STYLE="text-align: justify">the
                                         consummation of (i) any consolidation or merger of the Company where the stockholders
                                         of the Company, immediately prior to the consolidation or merger, would not, immediately
                                         after the consolidation or merger, beneficially own (as such term is defined in Rule
                                         13d-3 under the Act), directly or indirectly, shares representing in the aggregate more
                                         than fifty (50) percent of the voting shares of the Company issuing cash or securities
                                         in the consolidation or merger (or of its ultimate parent corporation, if any), or (ii)
                                         any sale or other transfer (in one transaction or a series of transactions contemplated
                                         or arranged by any party as a single plan) of all or substantially all of the assets
                                         of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paasheuvelweg 25a</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chamber of Commerce:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="width: 23%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">P.O. Box 22506</FONT></TD><TD STYLE="width: 25%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34275365</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1100 DA Amsterdam, NL</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">legal entity: uniQure biopharma B.V.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">T: +31 20 240 6000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">www.uniQure.com</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F: +31 20 240 6020</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">info@uniQure.com</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><IMG SRC="tv529829_ex10-2img01.jpg" ALT="">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.65in; text-align: justify">3</TD><TD STYLE="text-align: justify">Salary,
                                         bonus, equity and holiday allowance</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">3.1</TD><TD STYLE="text-align: justify">The                                          Employee&rsquo;s annual salary will be EUR
                                                                                                       348.000,00 gross (the &ldquo;Pro-rata Base Salary&rdquo;) based on 0.8 FTE (i.e., 80% of EUR 435,000), including
                                                                                                       an 8% holiday allowance. The salary, including the holiday allowance, shall be paid in
                                                                                                       12 equal, monthly instalments of EUR 29.000,00.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0; text-align: justify"></TD><TD STYLE="width: 42.55pt; text-align: justify">3.2</TD><TD STYLE="text-align: justify"><FONT STYLE="text-decoration: none">The
                                         Employee shall be eligible for a bonus payment amounting to a target amount of 40% of
                                         his Pro-rata Base Salary (the &ldquo;Target Bonus&rdquo;). The Employee&rsquo;s eligibility
                                         for a Target Bonus or any other bonus payment shall be dependent on the Employer guidelines
                                         and is at the full discretion of the Board. </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">3.3</TD><TD STYLE="text-align: justify"><FONT STYLE="text-decoration: none">Except
                                         as provided in clause 2.4, bonus payments, if any, will not be taken into account for
                                         the calculation of any possible severance payment upon termination of the Agreement.
                                         To be eligible for any bonus pursuant to this Agreement or otherwise pursuant to Employee&rsquo;s
                                         employment with Employer, Employee must be in service of Employer on the date any bonus
                                         is paid.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">3.4</TD><TD STYLE="text-align: justify">Subject
                                         to Board of Directors&rsquo; approval at the next regularly scheduled uniQure N.V. Board
                                         meeting after execution of this Agreement, the Employee shall be granted Restricted Stock
                                         Units totaling 15,000 (fifteen thousand) ordinary shares of uniQure N.V., the terms of
                                         which shall reflect the standard three-year vesting and other terms and conditions contained
                                         in the uniQure N.V.&rsquo;s Amended and Restated 2014 Share Incentive Plan. Such options
                                         will be approved by the Board of Directors of uniQure N.V. not later than at its next
                                         regularly scheduled meeting. The Executive will be eligible for future equity grants
                                         pursuant to the Company&rsquo;s policies and procedures, which shall also be subject
                                         to pro-ration related to the Employee&rsquo;s part-time status.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.65in; text-align: justify">4</TD><TD STYLE="text-align: justify">Overtime</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.6in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Employee undertakes to work overtime at the
    request of the Employer. The Employer does not pay any compensation for overtime.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.65in; text-align: justify">5</TD><TD STYLE="text-align: justify">Expenses</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">5.1</TD><TD STYLE="text-align: justify">The
                                         costs for travelling from home to office shall be compensated in accordance with the
                                         Employer policy.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">5.2</TD><TD STYLE="text-align: justify">To
                                         the extent that the Employer has given prior approval for business travels, the Employer
                                         shall reimburse reasonable travel and accommodation expenses relating to such business
                                         travel incurred by the Employee in the performance of his duties upon submission of all
                                         the relevant invoices and vouchers within 30 days following completion of the business
                                         travel.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.65in; text-align: justify">6</TD><TD STYLE="text-align: justify">Holidays</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">6.1</TD><TD STYLE="text-align: justify">The
                                         Employee is entitled to 30 business days holiday per year or a pro rata portion thereof
                                         if the Agreement commences and/or terminates during the calendar year and/or the Employee
                                         works part-time.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">6.2</TD><TD STYLE="text-align: justify">The
                                         statutory holiday days (20 days of the 30 per year on full time employment) shall be
                                         forfeited after 6 months after the end of the year in which the holiday days were accrued.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">6.3</TD><TD STYLE="text-align: justify">The
                                         Employer shall determine the commencement and the end of the holiday in consultation
                                         with the Employee. The Employee shall take his holidays in the period that the activities
                                         best allow this.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paasheuvelweg 25a</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chamber of Commerce:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="width: 23%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">P.O. Box 22506</FONT></TD><TD STYLE="width: 25%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34275365</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1100 DA Amsterdam, NL</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">legal entity: uniQure biopharma B.V.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">T: +31 20 240 6000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">www.uniQure.com</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F: +31 20 240 6020</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">info@uniQure.com</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><IMG SRC="tv529829_ex10-2img01.jpg" ALT="">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.65in; text-align: justify">7</TD><TD STYLE="text-align: justify">Illness</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.6in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">In the event of illness in the sense of section
    7:629 Dutch Civil Code, the Employee must report sick to the Employer as soon as possible, but no later than 9 a.m. on the
    first day of illness. The Employee undertakes to comply with the rules related to reporting and inspection in the case of
    illness, as adopted from time to time by the Employer.</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.65in; text-align: justify">8</TD><TD STYLE="text-align: justify">Insurance</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.6in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Employer will comply with the obligations under
    the Dutch Health Care Insurance Act.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.65in; text-align: justify">9</TD><TD STYLE="text-align: justify">Pension</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.6in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify">The Employee shall be entitled to participate
    in the pension scheme of the Employer following Employer guidelines.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.65in; text-align: justify">10</TD><TD STYLE="text-align: justify">Confidentiality
                                         obligation</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">10.1</TD><TD STYLE="text-align: justify">Both
                                         during the term of the Agreement and after the Agreement has been terminated for any
                                         reason whatsoever, the Employee shall not make any statements in any way whatsoever to
                                         anyone whomsoever (including other personnel of the Employer, unless these should be
                                         informed of anything in connection with the work they perform for the Employer), regarding
                                         matters, activities and interests of a confidential nature related to the business of
                                         the Employer and/or the Employer&rsquo;s affiliates, of which the Employee became aware
                                         within the scope of his work for the Employer and the confidential nature of which he
                                         is or should be aware (&ldquo;Confidential Information&rdquo;). The Confidential Information
                                         includes, <I>inter alia</I>, information about the Employer&rsquo;s products, processes
                                         and services, including but not limited to, information relating to research, development,
                                         inventions, manufacture, purchasing, engineering, marketing, merchandising and selling.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">10.2</TD><TD STYLE="text-align: justify">For
                                         all oral and written publications by the Employee, which can or could harm the interests
                                         of the Employer, prior approval from the Employer has to be obtained. This approval shall
                                         only be refused on sincere grounds based on those interests.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">10.3</TD><TD STYLE="text-align: justify">All
                                         information exchanged via the Employer&rsquo;s email system is considered to be Employer&rsquo;s
                                         proprietary information and should be taken care of accordingly.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">10.4</TD><TD STYLE="text-align: justify">The
                                         Employee agrees that the confidentiality obligations set forth in this clause 10 supersede
                                         the Employee&rsquo;s obligations to any other company, fund or other organization with
                                         which the Employee may have a relationship (&ldquo;Affiliated Entities&rdquo;) and that
                                         any Confidential Information that Employee receives will only be used within the scope
                                         of his employment under this Agreement or any successor agreement with Employer and will
                                         not be used during the course of his relationship, or communicated through by any means
                                         to, any Affiliated Entity.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.65in; text-align: justify">11</TD><TD STYLE="text-align: justify">Documents</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.6in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Employee is prohibited from in any way having
    documents and/or correspondence and/or other information carriers and/or copies thereof in his possession that belong to the
    Employer and/or to the Employer&rsquo;s affiliates, with the exception of the extent to which and as long as required for
    the performance of his activities for the Employer. In any event, the Employee is required, even without any request being
    made to that end, to return such documents and/or correspondence and/or other information carriers and/or copies thereof to
    the Employer immediately upon the end of the Agreement, or in the event the Employee is on non-active duty for any reason
    whatsoever.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paasheuvelweg 25a</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chamber of Commerce:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="width: 23%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">P.O. Box 22506</FONT></TD><TD STYLE="width: 25%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34275365</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1100 DA Amsterdam, NL</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">legal entity: uniQure biopharma B.V.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">T: +31 20 240 6000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">www.uniQure.com</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F: +31 20 240 6020</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">info@uniQure.com</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><IMG SRC="tv529829_ex10-2img01.jpg" ALT="">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.65in; text-align: justify">12</TD><TD STYLE="text-align: justify">Ban
                                         on ancillary jobs</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.6in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the term of the Agreement, without the prior
    written consent of the Employer, the Employee shall not accept any paid work or time-consuming unpaid work at or for third
    parties and will refrain from doing business for his own account, other than as provided in clause 1.4 above. For the avoidance
    of doubt the Employer shall not unreasonably withhold its consent for the Employee to take on any positions at third parties
    should the Employee fulfill such position as a Venture Partner of Forbion Capital Partners.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.65in; text-align: justify">13</TD><TD STYLE="text-align: justify">Non-competition
                                         and business relationship clause</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">13.1</TD><TD STYLE="text-align: justify">Both
                                         during the term of the Agreement and for a period of one year after the Agreement has
                                         been terminated for any reason whatsoever, without the prior written consent of the Employer,
                                         the Employee shall not be engaged or involved or have any share in any manner whatsoever,
                                         directly or indirectly, whether on his own behalf or for third parties, in any enterprise
                                         which conducts activities in a field similar to or otherwise competing with that of the
                                         Employer and/or the Employer&rsquo;s affiliates, nor act, in any manner whatsoever, directly
                                         or indirectly, whether on his own behalf or for third parties, as an intermediary in
                                         relation to such activities. The activities contemplated by clause 1.4 shall not be deemed
                                         to be in breach of this clause 13.1.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">13.2</TD><TD STYLE="text-align: justify">Both
                                         during the term of the Agreement and for a period of one year after the Agreement has
                                         been terminated for any reason whatsoever, without the prior written consent of the Employer,
                                         the Employee shall not perform or have performed professional services in connection
                                         with any product or research or development or commercialization that competes with products,
                                         or research or development or commercialization of Employer, directly or indirectly,
                                         whether on his own behalf or for third parties, nor enter into contacts, in that respect,
                                         directly or indirectly, whether on his own behalf or for third parties, with clients
                                         and/or relations of the Employer and/or the Employer&rsquo;s affiliates and/or purchasers
                                         of products and/or services of the Employer and/or the Employer's affiliates. The activities
                                         contemplated by clause 1.4 shall not be deemed to be in breach of this clause 13.2</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">13.3</TD><TD STYLE="text-align: justify">Clients
                                         and/or relations of the Employer and/or the Employer&rsquo;s affiliates such as set out
                                         in article 13.2 of this Agreement shall in all events mean relations of the Employer
                                         and/or the Employer&rsquo;s affiliates with which the Employer has or has had (business)
                                         contact in any manner whatsoever throughout the course of, or otherwise prior to the
                                         termination of, the Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">13.4</TD><TD STYLE="text-align: justify">Both
                                         during the term of the Agreement and for a period of one year after the Agreement has
                                         been terminated for any reason whatsoever, without the prior written consent of the Employer,
                                         the Employee shall refrain from becoming engaged or involved in any manner whatsoever,
                                         directly or indirectly, whether on his own behalf or for third parties, in actively enticing
                                         away, taking (or causing to have taken) into employment, nor make use of, in any manner
                                         whatsoever, directly or indirectly, whether on his own behalf or for third parties, the
                                         type of work of employees or persons who in a period of one year prior to the termination
                                         of the Agreement of the Employee are or have been in the employment of the Employer and/or
                                         the Employer&rsquo;s affiliates.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paasheuvelweg 25a</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chamber of Commerce:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="width: 23%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">P.O. Box 22506</FONT></TD><TD STYLE="width: 25%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34275365</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1100 DA Amsterdam, NL</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">legal entity: uniQure biopharma B.V.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">T: +31 20 240 6000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">www.uniQure.com</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F: +31 20 240 6020</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">info@uniQure.com</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><IMG SRC="tv529829_ex10-2img01.jpg" ALT="">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">13.5</TD><TD STYLE="text-align: justify">Employee
                                         acknowledges and agrees to adhere to this clause as the Employer has a serious business
                                         interest in binding the Employee to the non-competition and business relationship clause,
                                         due to the fact that (i) within the organization of the Employer competition-sensitive
                                         information as well as confidential information related to the Employer and its clients
                                         and relations, such as but not limited to products, or research or development or commercialization
                                         of Employer (&ldquo;Sensitive Business Information&rdquo;) are available and (ii) in
                                         the position of <FONT STYLE="text-decoration: none"><B>Executive Vice President, Research
                                         and Product Development </B></FONT>the Employee has access to this Sensitive Business
                                         Information and/or will become aware of this Sensitive Business Information and/or will
                                         maintain (commercial) contacts with clients, suppliers, competitors etc. Given the aforesaid
                                         considerations (i) and (ii) in this clause, combined with the education and capacities
                                         of the Employee, the Employer has a well-founded fear that its business interest will
                                         be harmed substantially if the Employee performs competing activities as set forth in
                                         clauses 13.1 up to and including 13.5 of the Agreement within a period of 12 months after
                                         termination of the Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.65in; text-align: justify">14</TD><TD STYLE="text-align: justify">Intellectual
                                         and industrial property</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">14.1</TD><TD STYLE="text-align: justify">The
                                         Employer is or will be considered to be, to the fullest extent allowed by law, the maker/producer/designer/breeder
                                         of all that which is made, created, improved, produced, designed, invented or discovered
                                         by the Employee during his activities performed for the Employer (the <B>Works</B>).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">14.2</TD><TD STYLE="text-align: justify">The
                                         Employee is obliged to fully and comprehensibly disclose all Works to the Employer in
                                         writing immediately after they are created or after the creation becomes known to the
                                         Employee, and in any case at the request of the Employer.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">14.3</TD><TD STYLE="text-align: justify">The
                                         Employee hereby transfers and assigns all his rights to and in connection with the Works
                                         to the Employer in advance.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">14.4</TD><TD STYLE="text-align: justify">The
                                         Employee is obliged, at first request of the Employer, to transfer and assign to the
                                         Employer all rights to and in connection with the Works that do not belong to the Employer
                                         by operation of law (<I>van rechtswege</I>), and that are not transferred to the Employer
                                         pursuant to article 14.3 of this Agreement. This concerns all rights, anywhere in the
                                         world, to and arising from or in connection with the Works. This obligation of the Employee
                                         remains in force even after the end of this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">14.5</TD><TD STYLE="text-align: justify">The
                                         Employee agrees to perform, to the extent necessary and/or at the request of the Employer,
                                         such further acts as may be necessary or desirable to apply for, obtain and/or maintain
                                         protection for the Works, <I>inter alia</I> by means of the establishment of intellectual
                                         and industrial property rights. The Employee hereby grants permission and power of attorney
                                         to the Employer to the extent necessary to carry out every required act on behalf of
                                         the Employee to obtain protection for the Works, or to transfer the Works and any rights
                                         relating thereto, to the Employer. The Employer will compensate the reasonable costs
                                         made in respect hereof, in so far as the payment that the Employee receives pursuant
                                         to article 3.1 of this Agreement cannot be considered as compensation for such costs.
                                         This obligation of the Employee remains in force even after the end of the Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">14.6</TD><TD STYLE="text-align: justify">The
                                         Employee acknowledges that the payment ex article 3.1 of this Agreement includes a reasonable
                                         compensation for any possible deprivation of any intellectual and industrial property
                                         rights. To the extent legally possible, the Employee hereby waives his right to any additional
                                         compensation with respect to the Works.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paasheuvelweg 25a</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chamber of Commerce:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="width: 23%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">P.O. Box 22506</FONT></TD><TD STYLE="width: 25%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34275365</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1100 DA Amsterdam, NL</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">legal entity: uniQure biopharma B.V.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">T: +31 20 240 6000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">www.uniQure.com</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F: +31 20 240 6020</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">info@uniQure.com</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><IMG SRC="tv529829_ex10-2img01.jpg" ALT="">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.65in; text-align: justify">15</TD><TD STYLE="text-align: justify">Gifts</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.6in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">In connection with the performance of his duties,
    the Employee is prohibited from accepting or stipulating, either directly or indirectly, any commission, reimbursement or
    payment, in whatever form, or gifts from third parties other than those covered under article 1.4. The foregoing does not
    apply to standard promotional gifts having little monetary value.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.65in; text-align: justify">16</TD><TD STYLE="text-align: justify">Penalty
                                         clause</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.6in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify">In the event the Employee acts in violation
    of any of the obligations under the articles 10 through 15 of this Agreement, the Employee shall, contrary to section 7:650
    paragraphs 3, 4 and 5 Dutch Civil Code, without notice of default being required, forfeit to the Employer for each such violation,
    a penalty in the amount of EUR 10.000,00 as well as a penalty of EUR 1.000,00 for each day such violation has taken place
    and continues. Alternatively, the Employer will be entitled to claim full damages.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.65in; text-align: justify">17</TD><TD STYLE="text-align: justify">Transfer
                                         of an undertaking</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.6in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Employee shall remain under the obligation to
    adhere the set out in the articles 10 through 16 of this Agreement vis-&agrave;-vis the Employer, if the enterprise of the
    Employer or a part thereof is transferred to a third party within the meaning of section 7:662 and onwards Dutch Civil Code
    and this Agreement terminates before or at the time of such transfer, whereas in the event of continuation of the Agreement
    the Employee would have entered the employment of the acquirer by operation of law.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.65in; text-align: justify">18</TD><TD STYLE="text-align: justify">Other
                                         arrangements</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.6in">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">Subject to the provisions in this Agreement, the arrangements
    related to employment conditions adopted by the Employer from time to time, as laid down in the Employee Handbook are applicable.
    A copy of these arrangements has been provided to the Employee. By signing this agreement, the Employee acknowledges to have
    received and understood the Employee Handbook and the Insider Trading Policy.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.65in; text-align: justify">19</TD><TD STYLE="text-align: justify">Employment
                                         costs regulation</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.6in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">The conditions of employment costs regulation determined
    by the Employer apply. In this context, the Employer reserves the right at its sole discretion to modify certain fringe benefits,
    without any compensation in return.</TD></TR>
</TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.65in; text-align: justify">20</TD><TD STYLE="text-align: justify">Amendment
                                         clause</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0; text-align: justify"></TD><TD STYLE="width: 42.55pt; text-align: justify">20.1</TD><TD STYLE="text-align: justify">The
                                         Employer reserves the right to unilaterally amend the Agreement and the arrangements
                                         referred to in article 18 of this Agreement if it has such a serious interest in that
                                         respect entailing that the interests of the Employee must yield to that in accordance
                                         with standards of reasonableness and fairness.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0; text-align: justify"></TD><TD STYLE="width: 42.55pt; text-align: justify">20.2</TD><TD STYLE="text-align: justify">The
                                         Employer reserves the right to unilaterally amend the Agreement and the arrangements
                                         referred to in article 18 of this Agreement in the event of a relevant amendment of the
                                         law.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paasheuvelweg 25a</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chamber of Commerce:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="width: 23%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">P.O. Box 22506</FONT></TD><TD STYLE="width: 25%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34275365</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1100 DA Amsterdam, NL</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">legal entity: uniQure biopharma B.V.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">T: +31 20 240 6000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">www.uniQure.com</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F: +31 20 240 6020</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">info@uniQure.com</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><IMG SRC="tv529829_ex10-2img01.jpg" ALT="">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.65in; text-align: justify">21</TD><TD STYLE="text-align: justify">Applicable
                                         law, no collective labour agreement</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">21.1</TD><TD STYLE="text-align: justify">This
                                         Agreement is governed by Dutch law.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in; text-align: justify"></TD><TD STYLE="width: 0.6in; text-align: justify">21.2</TD><TD STYLE="text-align: justify">The
                                         Agreement is not subject to any collective labour agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THIS AGREEMENT has been entered into on
the date stated at the beginning of this Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
<TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><B>uniQure biopharma B.V.</B></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><B>Employee</B></TD></TR>
<TR STYLE="vertical-align: bottom">
<TD STYLE="font-size: 10pt; text-align: justify; width: 5%">&nbsp;</TD>
<TD STYLE="text-align: left; width: 44%">&nbsp;</TD>
<TD STYLE="font-size: 10pt; width: 2%">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: justify; width: 49%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
<TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify; border-bottom: Black 1pt solid">/s/ Lilly Burggraaf</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: justify; border-bottom: Black 1pt solid">/s/ Sander van Deventer</TD></TR>
<TR STYLE="vertical-align: bottom">
<TD STYLE="font-size: 10pt; text-align: justify">By:</TD>
<TD STYLE="font-size: 10pt; text-align: justify">Lilly Burggraaf</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: justify">By: Sander van Deventer</TD></TR>
<TR STYLE="vertical-align: bottom">
<TD STYLE="font-size: 10pt; text-align: justify">Title:</TD>
<TD STYLE="font-size: 10pt; text-align: justify">VP, Global Human Resources</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paasheuvelweg 25a</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chamber of Commerce:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="width: 23%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">P.O. Box 22506</FONT></TD><TD STYLE="width: 25%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34275365</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1100 DA Amsterdam, NL</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">legal entity: uniQure biopharma B.V.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">T: +31 20 240 6000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">www.uniQure.com</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F: +31 20 240 6020</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">info@uniQure.com</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><IMG SRC="tv529829_ex10-2img01.jpg" ALT="">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<!-- Field: Split-Segment; Name: 2 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Exhibit A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Job description Executive Vice President,
Research &amp; Product Development</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Reporting to the Chief Executive Officer,
the Executive Vice President, Research &amp; Product Development will be responsible for the Employer&rsquo;s research, scientific,
product development and technology platform strategy and activities in support of uniQure&rsquo;s corporate strategy, including
basic and applied research projects, as well as the research and development of new processes, technologies and products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, the Executive Vice President,
Research &amp; Product Development will also provide guidance on scientific-related matters within the Company and represent uniQure
at scientific/medical conferences, as well as with investors and regulatory agencies. Duties will be performed on behalf of Employer
and, as needed, Employer&rsquo;s subsidiaries and affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Job Responsibilities:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Develop and implement strategies related
to research, product development (including analytical development, process development and vector development) and technology
development (including new AAV vectors, promoters, etc.) that support and enhance the corporate long-term plan;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Effectively communicate a vision and plan
related to new product research and development, as well as scientific and technological matters;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In collaboration with the Chief Executive
Officer, Chief Medical Officer, Commercial leader and Business Development leader, define and support a process and criteria for
identifying new targets, indications and potential gene therapy product candidates;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Provide scientific guidance on strategic
and operating decisions, setting strategy and performance goals;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Regularly reporting to the Board and other
members of the organization to ensure transparency regarding the progress of research and platform development programs;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Work closely with the Executive Vice President,
Operations, Chief Medical Officer and other key leaders to ensure execution on a global R&amp;D and technology strategy;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Provide strong scientific leadership for
the uniQure research, nonclinical, product development and enabling technology development teams;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paasheuvelweg 25a</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chamber of Commerce:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="width: 23%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">P.O. Box 22506</FONT></TD><TD STYLE="width: 25%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34275365</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1100 DA Amsterdam, NL</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">legal entity: uniQure biopharma B.V.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">T: +31 20 240 6000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">www.uniQure.com</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F: +31 20 240 6020</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">info@uniQure.com</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><IMG SRC="tv529829_ex10-2img01.jpg" ALT="">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Work closely and collaboratively with Program
Management in the execution of R&amp;D stage-gates;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Lead the effort to translate discovery research
into clinical-ready product candidates;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Establish and/or help to maintain relationships
with KOL&rsquo;s and academic institutions, and serve as a key liaison between the Company and its external scientific advisors
and the investment community;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Identify and support the Business Development
leader in evaluating collaboration opportunities to gain access to key capabilities and provide leadership in managing such collaborations;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Provide scientific expertise in support of
product and clinical development activities;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Actively participate in the evaluation and
implementation of business development opportunities, including collaborations, in-licensing and acquisitions of product candidates
and technologies, including due diligence as required;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Actively participate in leadership team meetings,
Board meetings and other key operating mechanisms required of senior management and by the Chief Executive Officer;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Make and attend scientific and investor presentations,
and participate in key scientific, medical and investor conferences; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Support the establishment of and collaboration
with a Scientific Committee of the Board that will work with management and the Board of Directors to provide feedback and oversite
regarding R&amp;D and technology strategy; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Develop budgets for relevant functional responsibilities,
subject to approval by the Chief Executive Officer and Chief Accounting Officer, and ensure execution within approved targets;
</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Foster and develop an innovative and productive
organization of talented employees, including the management, motivation, recruitment and evaluation of personnel;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Responsible for definition, implementation,
maintenance and continued improvement of processes and systems, supported by meaningful Key Performance Indicators (KPI&rsquo;s);</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Constructively and collaboratively interacts
with staff of other disciplines, such as Finance, Operations, Human Resources, Commercial, Legal, Business Development, Investor
Relations and Clinical Development to ensure efficient day-to-day cooperation and success for the business; and</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">  Any other duties as may from time to time be assigned by the Employer and which are commensurate with Executive Vice President, Research &amp; Product Development&rsquo;s senior executive status.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paasheuvelweg 25a</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chamber of Commerce:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="width: 23%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">P.O. Box 22506</FONT></TD><TD STYLE="width: 25%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34275365</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1100 DA Amsterdam, NL</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">legal entity: uniQure biopharma B.V.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">T: +31 20 240 6000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">www.uniQure.com</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR><TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F: +31 20 240 6020</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">info@uniQure.com</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>tv529829_ex10-3.htm
<DESCRIPTION>EXHIBIT 10.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit&nbsp;10.3</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">September 16, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Scott T. McMillan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">109 Hayward Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acton, MA 01720</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Re: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Separation from Employment</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Scott,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As we have discussed, the purpose of this
letter agreement (&ldquo;Agreement&rdquo;) is to set forth our mutual understanding and agreement concerning the terms and conditions
of your separation from employment with uniQure, Inc. (the &ldquo;Company&rdquo;), which generally are described in the Employment
Agreement between you and the Company dated July 10, 2017 (the &ldquo;Employment Agreement&rdquo;). In consideration of the mutual
promises set forth below, we have agreed as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify"><U>Separation from Employment</U>. You will resign, and your separation from employment shall be
effective on August 31, 2019 (your &ldquo;<U>Separation Date</U>&rdquo;). You shall have relinquished as of that date any and all
positions that you have held with the Company. You shall not be considered an employee of the Company for any purpose after that
date. Effective as of August 19, 2019 through and including the Separation Date (the &ldquo;Garden Leave Period&rdquo;), you will
be on garden leave until the Separation Date without access to the Company&rsquo;s facilities or electronic systems and your responsibility
and duties during that time will be to provide reasonable consultation and assistance on an as needed basis to the Chief Executive
Officer and the Executive Vice President, Operations (the &ldquo;Company Officers&rdquo;) with any transition matters or issues.
All business transacted on behalf of the Company during the Garden Leave Period shall be only with the Company Officers.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify"><U>Final Compensation</U>. Regardless of whether you accept this Agreement, on your Separation
Date, the Company shall provide you with your Accrued Benefits, as that term is defined in the Employment Agreement. Specifically,
the Company shall provide you with final payment of base salary due for time worked through the Separation Date as well as payment
for any accrued but unused vacation time. You agree that such payment represents all compensation to which you are entitled in
connection with your employment. Any additional requests by you for reimbursement of business expenses must be submitted for payment
using the Company&rsquo;s standard expense reimbursement system no later than the Separation Date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify"><U>Separation Payment</U>. Subject to: (i) the Company&rsquo;s receipt of this Agreement signed
by you; (ii) your full acceptance of the terms of, and full performance under, this Agreement (including, without limitation, your
acceptance of the general release of legal claims contained in Paragraph 9 below (the &quot;General Release&quot;)); (iii) your
satisfactory performance of the responsibilities and duties of your position with the Company up through your Separation Date,
and (iv) the expiration of the seven (7) day revocation period contained in Paragraph 11 below (the &quot;Revocation Period&quot;)
without revocation):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Scott T. McMillan</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Separation Agreement</P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
the Company agrees to provide you with a lump sum severance payment equal to 100% of your annual base salary of Three Hunderd Ninety-One
Thousdand Six Hundred Forty-Four Dollars ($391,644) less all applicable federal, state and local taxes and other withholdings (the
&quot;Separation Payment&quot;). The Separation Payment will be made to you no later than thirty (30) days following the date you
sign and deliver this Agreement to the Company and after the Revocation Period has expired without any notice of revocation by
you. You will also receive an accelerated vesting of the Performance Share Units grant to you dated January 26, 2018 as provided
in Section 6 below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Provided that you and your eligible dependents, if any, are participating in the Company&rsquo;s group health, dental and vision
plans on the termination date and elect on a timely basis to continue that participation in some or all of the offered plans through
the federal law commonly known as &ldquo;COBRA,&rdquo; the Company will pay or reimburse you for your full COBRA premiums (i.e.,
employer and employee portion) until the earlier to occur of: (a) eighteen (18) months from the Separation Date, (b) the date you
become eligible to enroll in the health, dental and/or vision plans of another employer, (c) the date you (and/or your eligible
dependents, as applicable) are no longer eligible for COBRA coverage, or (d) the Company in good faith determines that payments
under this paragraph would result in a discriminatory health plan pursuant to the Patient Protection and Affordable Care Act of
2010, as amended, and any guidance or regulations promulgated thereunder (collectively, &ldquo;PPACA&rdquo;). You agree to notify
the Company promptly if you become eligible to enroll in the plans of another employer or if you or any of your dependents cease
to be eligible to continue participation in the Company&rsquo;s plans through COBRA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify"><U>Tax Provision</U>. In connection with the Separation Payment provided to you pursuant to this
Agreement, the Company shall withhold and remit to the tax authorities the amounts required under applicable law, and you shall
be responsible for all applicable taxes with respect to such Separation Payment under applicable law. The Company does not guarantee
any particular tax effect for any of the payments or other consideration set forth in this Agreement, and you shall be solely responsible
and liable for the satisfaction of all taxes, penalties and interest that may be imposed on you or for your account in connection
with the Agreement (including any taxes, penalties and interest under IRC Section 409A), and the Company shall not have any obligation
to indemnify or otherwise hold you (or any beneficiary) harmless from any or all of such taxes, penalties or interest. You acknowledge
that you are not relying upon advice or representation of the Company with respect to the tax treatment of any of the separation
benefits set forth in this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">5.</TD><TD STYLE="text-align: justify"><U>Health Insurance Continuation</U>. Regardless of whether you accept this Agreement, you will
remain on the Company&rsquo;s insured health plan at the level(s) you are currently enrolled, through August 31, 2019. Notice of
your rights and obligations concerning continuation of coverage shall be sent to you under separate cover in accordance with applicable
law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Scott T. McMillan</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Separation Agreement</P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">6.</TD><TD STYLE="text-align: justify"><U>Status of Employee Benefits and Stock Options</U>. Except as otherwise expressly provided in
Section 5 of this Agreement, your participation in all employee benefit plans of the Company shall end as of your Separation Date
in accordance with the terms of those plans. Information will be provided on terminating participation in all plans, including
either maintaining your existing 401k account, or rolling it over to another provider. The Company confirms that you will have
vested Stock Options, Performance Share Units (&ldquo;PSUs&rdquo;), and Restricted Share Units (&ldquo;RSU&rsquo;s&rdquo;) as of
your Separation Date pursuant to the terms of your grants. Stock Options may be exercised pursuant to the terms and conditions
of your Share Option Agreements and the Company&rsquo;s Amended and Restated 2014 Share Incentive Plan. Your Performance Share
Units granted in January 2018 (totaling 7045 shares) will have a Vesting Date (as defined in the grant agreement) of September
19, 2019. You will not be eligible to participate in the Company Employee Stock Purchase Plan (&ldquo;ESPP&rdquo;) for the offering
period beginning September 1, 2019. For the offering period from June 1, 2019 through August 31, 2019, the Company will refund
any payroll contributions that you made pursuant to the ESPP, and no stock will be purchased on your behalf. This Agreement does
not grant or promise to grant any equity, and, except where expressly provided, does not modify the terms of any prior grant of
equity or modify the terms of any agreement signed pursuant to a grant of equity. The terms of the grants of equity and agreements
signed pursuant to grants of equity shall control in case of conflict with this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">7.</TD><TD STYLE="text-align: justify"><U>Confidentiality</U>. As a material inducement to the Company to enter into this Agreement, you
agree to keep the fact of this Agreement (including any negotiations or discussions related hereto), the amount of the payments,
other consideration, and the terms of this Agreement (&ldquo;Agreement-Related Information&rdquo;), in complete confidence. Except
as you may be required by local, state or federal law or regulation or by compulsory process of law, and provided that in case
of such requirement you shall immediately, unless precluded by law, notify the Company of such requirement in writing, you agree
that neither you nor any person acting by, through, under, or in concert with you will, at any time, disclose Agreement-Related
Information, except for disclosures: (i) to an attorney of your choice who may be advising you in connection with this Agreement;
(ii) to your accountant or tax preparer; or (iii) to your immediate family, provided that all such persons to whom you disclose
such information are first advised by you prior to such disclosure of the confidential nature of the information and your obligations
under this Agreement, and further provided that the subsequent disclosure by any such persons of the amount of this settlement
or the terms of this Agreement will be treated as if you had made such disclosure; and (iv) and, in any event, you shall at no
time disclose Agreement-Related Information to any current or former employee of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Scott T. McMillan</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Separation Agreement</P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">8.</TD><TD STYLE="text-align: justify"><U>Non-Disparagement/Cooperation</U>. You agree, to the extent permitted by law, that you will
not, at any time after the date hereof, make any remarks or comments, orally or in writing, to any customer, potential customer,
partner, supplier, employee, shareholder, potential investor, or any other person, which or who have, or could reasonably be anticipated
to have, business dealings with the Company, which remarks or comments reasonably could be construed to be derogatory or disparaging
to the Company or any of its shareholders, officers, directors, employees, attorneys or agents, or which reasonably could be anticipated
to be damaging or injurious to the Company&rsquo;s reputation or good will or to the reputation or good will of any person associated
with the Company. Notwithstanding the above, your non-disparagement obligation shall not prohibit you from testifying truthfully
in any legal proceeding.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">9.</TD><TD STYLE="text-align: justify"><U>General Release</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">(a)&nbsp;&nbsp;&nbsp;
 You hereby irrevocably
and unconditionally release, acquit and forever discharge the Company, its parent entities and corporations, subsidiaries (whether
wholly or partially owned), divisions, affiliates, predecessors, successors and assigns, and its and their respective current and
former partners, owners, agents, directors, officers, fiduciaries, employees, supervisors, managers, representatives, attorneys,
insurers and reinsurers, and all persons and entities acting by, through, under or in concert with the Company or any of the aforementioned
entities or individuals, in their personal and professional capacities (collectively the &quot;Releasees&quot;), from any and all
claims, demands, and causes of action of whatever kind or nature, including without limitation, all claims, demands, and causes
of action arising from your employment or separation from employment with the Company, that you or your heirs, executors, administrators,
successors or assigns have, may have, or have at any time had, prior to the date you sign this Agreement against the Releasees,
or any of them, whether arising under tort, contract, or other law and whether arising under state, federal, or other law including,
but not limited to, Title VII of the Civil Rights Act of 1964 and as amended by the Civil Rights Act of 1991, 42 U.S.C. &sect;&sect;
2000e, <I>et seq.; </I>the Americans with Disabilities Act, 42 U.S.C. &sect;&sect; 12101, <I>et seq,</I> as amended; the Age Discrimination
in Employment Act (including, without limitation, the Older Workers' Benefit Protection Act), 29 U.S.C. &sect;&sect; 623, <I>et
seq.; </I>the National Labor Relations Act, as amended, 29 U.S.C., &sect; 151 <I>et seq.; </I>the Occupational Safety and Health
Act, as amended; the Immigration Reform Control Act, as amended; &sect; 503 of the Rehabilitation Act of 1973, 29 U.S.C. &sect;&sect;
701, <I>et seq.;</I> the Civil Rights Act of 1866, 42 U.S.C. &sect; 1981; except as otherwise provided herein the Consolidated
Omnibus Budget Reconciliation Act of 1985, 42 U.S.C. &sect; 1395(c); Executive Order 11246; the Employee Retirement Income Security
Act, 29 U.S.C. &sect;&sect; 1132 (a)(l)(B), <I>et seq.; </I>the federal Workers Adjustment and Retraining Notification Act, 29
U.S.C. &sect;&sect; 2101 et seq.; Sarbanes- Oxley Act of 2002, Public Law 107-204, including whistleblowing claims under 18 U.S.C.
&sect;&sect; 1514A and 1513(e); the Family and Medical Leave Act, 29 U.S.C. &sect;&sect; 2601 <I>et seq; </I>all claims arising
out of the claims under the MA Fair Employment Practices Act, M.G.L. c. 151B, the MA Wage and Hour laws, M.G.L. c. 149, et. al.,
M.G.L. c. 93, and all other claims and rights under any other federal, state, and local statutory and common law, including but
not limited to public policy, contract and tort and any and all claims arising from any injuries or damages suffered by you, for
attorney's fees, costs, non- payment, or any other claim or damage you could assert against the Company and/or the Releasees. For
the avoidance of doubt, this release includes any claims under the under the Massachusetts Wage Act and State Overtime Laws, including
without limitation G.L. c. 149 &sect; 148, 150 <I>et seq. </I>and G.L. c. 151 &sect; lA <I>et seq. </I>You promise not to sue any
of the Releasees on any of these released claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Scott T. McMillan</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Separation Agreement</P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
You represent and warrant to the Company that no portion of any claim, demand, cause of action, or other matter released by you
herein, nor any portion of any recovery or settlement to which you might be entitled from any Releasee, has been assigned or transferred
to any other person or entity, either directly or by way of subrogation or operation of law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
You acknowledge that you have been granted by the Company all requested paid and/or unpaid leave to which you may have been entitled.
You represent that you are not aware of any facts that would support a claim by you against any of the Releasees for any violation
of the Family and Medical Leave Act. You further acknowledge that you have been properly paid for all time worked and are unaware
of any facts that would support a claim by you against any of the Releasees for any claim of unpaid wages or overtime or any other
violation of the Fair Labor Standards Act or state wage and hour law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Notwithstanding
the above, this Release does not include and shall not preclude&nbsp;(a) any rights to any vested benefits or vested rights under
employee benefit plans under the Employee Retirement Income Security Act (29 U.S.C. &sect; 1001 et seq.), as amended; (b) any claims
arising from a breach of this Agreement or rights to enforce this Agreement; (c) any action or proceeding against the Company for
acts, incidents, occurrences, or inactions occurring after the execution of this Agreement and (d) any rights to indemnification
that exist as of the Separation Date by the Company and/or the Company&rsquo;s insurers from any claims against you by any third
party involving your employment with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">10.</TD><TD STYLE="text-align: justify"><U>Protected Rights</U>. You understand that nothing contained in this Agreement limits your ability
to file a charge or complaint with the Equal Employment Opportunity Commission, the National Labor Relations Board, the Occupational
Safety and Health Administration, the Securities and Exchange Commission or any other federal, state or local governmental agency
or commission (&ldquo;Government Agencies&rdquo;). You further understand that this Agreement does not limit your ability to communicate
with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government
Agency, including providing documents or other information, without notice to the Company. You understand that you waive and release
any personal entitlement to reinstatement, back pay, or any other types of damages, or injunctive relief, in connection with any
actions taken by you on your behalf on your complaint or charge. You understand that by executing the General Release, you are
forever releasing and waiving any and all claims against the Releasees.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Scott T. McMillan</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Separation Agreement</P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">11.</TD><TD STYLE="text-align: justify"><U>Acknowledgments</U>. You acknowledge and agree that you understand the meaning of this Agreement
and that you freely <U>and</U> voluntarily enter into it and the General Release. You agree that no fact, evidence, event, or transaction,
whether known or unknown, shall affect in any manner the final and unconditional nature of this Agreements and the General Release.
Pursuant to the Older Workers Benefit Protection Act, you acknowledge that you have been advised:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
that you have twenty-one (21) days to consider this Agreement and General Release;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
any modifications to this Agreement, whether material or immaterial, will not restart the twenty-one (21) day consideration period;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1in; text-align: justify; text-indent: 0in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
to consult with an attorney prior to executing this Agreement and General Release;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1in; text-align: justify; text-indent: 0in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
by signing this Agreement and General Release you will give up important legal rights, including the right to sue the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1in; text-align: justify; text-indent: 0in"> (v)&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">this Agreement and General Release does not release any claims that arise after the execution of this Agreement and General Release; and</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1in; text-align: justify; text-indent: 0in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
for a period of seven (7) days after executing this Agreement and General Release, you may revoke this Agreement and General Release
by providing written notice of said revocation to me at the address of the Company set forth above, and this Agreement and General
Release shall not become effective or enforceable until said seven-day period has expired without your revocation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in">In the event that you execute this Agreement
and General Release prior to the expiration of the twenty-one (21) day period during which you may consider it, you represent and
acknowledge that you have done so voluntarily and of your own free will without any coercion or compulsion of any nature by the
Company or anyone associated with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">12.</TD><TD STYLE="text-align: justify"><U>Acknowledgement of Confidentiality, Developments and Restrictive Covenants Agreement</U>. You
acknowledge that you are bound by the Company&rsquo;s Confidentiality, Developments, and Restrictive Covenants Agreement, which
copy is attached here as Exhibit 1 (the &ldquo;Confidentiality Agreement&rdquo;), including, without limitation, the provisions
regarding confidentiality, disclosure and assignment of inventions, non-competition, non-solicitation, disclosure of certain provisions
to future employers, tolling of post-employment obligations, and return of Company property. You further acknowledge that, pursuant
to Section 8 of the Confidentiality Agreement, the Confidentiality Agreement shall survive your separation from the Company. (In
case of a conflict between this Agreement and the Confidentiality Agreement, this Agreement shall control). You also acknowledge
and represent that you have returned all property of the Company as required in Section 19 of the Confidentiality Agreement, including,
without limitation, all documents, devices, equipment, keys, security passes, credit cards, hardware, data, databases, source code,
object code, and data or computer programming code stored on an optical or electronic medium, and any copies thereof, relating
to uniQure&rsquo;s business and affairs, including any Confidential Information or any reference thereto, and you further represent
that you are in compliance with Section 19 of the Confidentiality Agreement. Notwithstanding the foregoing, nothing in Exhibit
1 or set forth herein is intended to or shall interfere with your rights under the Defend Trade Secrets Act of 2016 which provides,
in part, that &ldquo;[a]n individual shall not be held criminally or civilly liable under any federal or state trade secret law
for the disclosure of a trade secret that (A) is made (i) in confidence to a federal, state, or local government official, either
directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation
of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Scott T. McMillan</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Separation Agreement</P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">13.</TD><TD STYLE="text-align: justify"><U>Consulting</U>. You agree that you will provide consulting services to the Company as requested
on an as-needed basis for the period from September 1, 2019 through and including October 31, 2019 (the &ldquo;Consulting Period&rdquo;).
You will provide consulting services consistent with your current position with the Company and assist in the transition of the
manufacturing and operations organization. Such services will be directed by the Executive Vice President, Operations, and may
include consulting services related to manufacturing, operations, product development, project management, human resources issues,
and other related fields. The services shall be limited to no more than eight hours per week. As compensation, you will receive
payments totaling thirteen thousand ninety-one dollars ($13,091.00) (the &ldquo;Consulting Fee&rdquo;). The Consulting Fee will
be paid in two installments: one-half with the Separation Payment and one-half within thirty days of the end of the Consulting
Period. For clarity, the parties intend that your grants of equity in the Company will continue to vest during the Consulting Period
on the same terms as if you had remained an employee of the Company during that period, and will cease to vest immediately following
the end of the Consulting Period.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">14.</TD><TD STYLE="text-align: justify"><U>Governing Law and Interpretation</U>. This Agreement shall be construed in accordance with the
laws of the Commonwealth of Massachusetts without regard to choice or conflict of law principles. The language of all parts of
this Agreement shall be construed as a whole, according to its fair meaning, and not strictly for or against either party.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">15.</TD><TD STYLE="text-align: justify"><U>Interpretation of Agreement</U>. This Agreement sets forth the entire agreement between the
parties pertaining to the subject matter hereof. Notwithstanding the foregoing, this Agreement does not abrogate, limit, or otherwise
impair any of the Company&rsquo;s rights or any of your post-employment obligations under the Confidentiality, Developments and
Restrictive Covenants Agreement. Likewise, this Agreement does not supersede or impair any of the terms or condition of any Performance
Share Unit Agreement, Share Option Agreement, or the Company&rsquo;s Amended and Restated 2014 Share Incentive Plan.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Scott T. McMillan</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Separation Agreement</P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">16.</TD><TD STYLE="text-align: justify"><U>No Reliance</U>. You represent and acknowledge that, in executing this Agreement, you do not
rely and have not relied upon any representation or statement outside this written agreement made by any of the Releasees or by
<U>any</U> of the Releasees&rsquo; agents, representatives or attorneys with regard to the subject matter, basis or effect of this
Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">17.</TD><TD STYLE="text-align: justify"><U>Waiver</U>. Failure to insist on compliance with any term, covenant or condition contained in
this Agreement shall not be deemed a <U>waiver</U> of that term, covenant or condition, nor shall any waiver or relinquishment
of any right or power contained in this Agreement at any one time or more times be deemed a waiver or relinquishment of any right
or power at any other time or times.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">18.</TD><TD STYLE="text-align: justify"><U>Severability and Modification</U>. Should any term or provision of this Agreement be declared
illegal, invalid or unenforceable by any court of competent jurisdiction and if such provision cannot be modified to be enforceable,
such provision shall immediately become null and void, leaving the remainder of this Agreement in full force and effect. Provided
however, if your General Release i<FONT STYLE="color: windowtext">s found invalid, illegal, and/or unenforceable, you agree to
enter into a full and General Release with the Company that is not invalid, illegal and/or unenforceable without payment of additional
consideration. </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">19.</TD><TD STYLE="text-align: justify"><U>Amendment</U>. This Agreement shall be binding upon the parties and may not be modified in any
manner, except by an instrument in writing of concurrent or subsequent date signed by duly authorized representatives of the parties
hereto. This Agreement is binding upon and shall inure to the benefit of the parties and their respective agents, assigns, heirs,
executors, successors and administrators.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">20.</TD><TD STYLE="text-align: justify"><U>Representation</U>. You represent that the Company has advised you, and you have had the opportunity,
to thoroughly discuss <U>all</U> aspects of this Agreement with legal counsel, that you have read and understand the provisions
herein, and that you are voluntarily entering into this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">uniQure, Inc.</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">/s/ Matthew Kapusta</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%">By:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Matthew Kapusta</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Scott T. McMillan</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Separation Agreement</P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">AGREED TO AND EXECUTED THIS 16<SUP>th</SUP> DAY OF SEPTEMBER
    2019.</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-bottom: Black 1pt solid">/s/ Scott T. McMillan</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Scott T. McMillan</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Scott T. McMillan</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Separation Agreement</P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>EXHIBIT 1</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Confidentiality,
Developments, and Restrictive Covenants Agreement</B></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 10; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>qure-20190916.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.0bc -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +K85w7xRiXgen8uNbXAsWa2C2bPtzp5xSekhuWh8bfmqjy0q/HqEGSv4w7TWIewH -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:qure="http://uniqure.com/20190916" elementFormDefault="qualified" targetNamespace="http://uniqure.com/20190916">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://uniqure.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="qure-20190916_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="qure-20190916_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>qure-20190916_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.0bc -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>qure-20190916_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.0bc -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://uniqure.com/role/Cover" xlink:href="qure-20190916.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://uniqure.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tv529829_ex10-2img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv529829_ex10-2img01.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  S -H# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^^_&=V1R
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M^"_C31?$V@23.UKH7C2670];L(ADB#^TK*PO-'U7DD>?/;Z8!QNRQKQS1?\
M@EA^U'J5_%:ZA;^ _#MI,Q\[4[KQ0+U((L')\G2]-GN+@CKU;'.>XK_.S/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
&**** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>10
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tv529829_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "tv529829_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "qure-20190916_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "qure-20190916_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "qure-20190916.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 57,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 97,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "qure",
   "nsuri": "http://uniqure.com/20190916",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tv529829_8k.htm",
      "contextRef": "From2019-09-15to2019-09-16",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://uniqure.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tv529829_8k.htm",
      "contextRef": "From2019-09-15to2019-09-16",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The start date of the period covered in the document, in CCYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://uniqure.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r10": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r11": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r12": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r13": {
   "Name": "Forms 10-K, 20-F, 40-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d-1"
  },
  "r14": {
   "Name": "Forms 20-F, 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220 and 240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>tv529829_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="qure-20190916.xsd" xlink:type="simple"/>
    <context id="From2019-09-15to2019-09-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590560</identifier>
        </entity>
        <period>
            <startDate>2019-09-15</startDate>
            <endDate>2019-09-16</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2019-09-15to2019-09-16">0001590560</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2019-09-15to2019-09-16">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2019-09-15to2019-09-16">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2019-09-15to2019-09-16">2019-09-16</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2019-09-15to2019-09-16">uniQure N.V.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2019-09-15to2019-09-16">P7</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2019-09-15to2019-09-16">001-36294</dei:EntityFileNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2019-09-15to2019-09-16">Paasheuvelweg 25a</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode contextRef="From2019-09-15to2019-09-16">1105 BP</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown contextRef="From2019-09-15to2019-09-16">Amsterdam</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="From2019-09-15to2019-09-16">NL</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="From2019-09-15to2019-09-16">31</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2019-09-15to2019-09-16">20-566-7394</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2019-09-15to2019-09-16">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2019-09-15to2019-09-16">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2019-09-15to2019-09-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2019-09-15to2019-09-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2019-09-15to2019-09-16">Ordinary Shares, par value &#x20ac;0.05 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2019-09-15to2019-09-16">QURE</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2019-09-15to2019-09-16">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2019-09-15to2019-09-16">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>13
<FILENAME>0001410578-19-001349-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001410578-19-001349-xbrl.zip
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M@<1&G!R(%.@]9H-!9H[?"-7LGL/M)^!'N%'<&W/MB5)9\D6J/'/4@GSMSBW
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M>? V6S-RX!RZT-]@\DJV<)G-&-;1M>!&GLJ@*1T(T" "A?=8T^[7(X*KH-K
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M6H]A&%RJOQ?T\7H EXQ5K .5Q0&]HHZ#)*OR0)5!/@QZ]0C&#W:V0OC_]HL
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MR.+0=8#-.1$'N.N") 495^O+T-CW-HN[FW#^NK6/33@I;B8*XP+LU(0Z0E6
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M%NYZO@QW+<-=/VNXZZ$J*@O:609^>V#L%LIMI>*SF6Q'ZV_$HVH&NQK5E?%
M_^M?J>W:(L>7F$4S9KO@%#7L]I:EWD8)R:-(E83Z'@81O ,LO10/O#IXC6WC
MX-B&F5'Q@9B),_:91%-0U\$F .*!7F;P_=@DH*N]3 :.L.%((B78H;[$-5+5
MI8>DYBI &_T&9DEU2.JXJK!D$#7/]A7H9%K';@E2OPAC>QT*&.Q-8-EC;HP0
M:X4=%I9$]".(:&$JLAZ^>>3D>P%M(X2N8)2'=]6VFXS+VLM(-"VMR(*?=64U
M:!C=DVWZ%=Q<FC3!@45@,()A%@I6+EH1[%EO5P^T_>H@8\GW+IW!9E:@%> R
M*$*R7NUXEYF97.U*^Q"_5SD+<FI#4*LKG,0W,8SG/_[:>!465%"DV43R3A&,
M$78)FV@0&@ %A9=,]]V=95\7#P\8)-FNDLX_W[SG(<7N[]]F+Q2_CQ?;Z[-S
M@29+#&]S%/JJ;FXL,:0#\+"5 -#A\V>0R4:R$@4<'1YQXSL1181R@')&44Q?
M3Y94\_VI1B]<,'S(I\<Q'UI(!7[>]\=V^W4NP>""XH^<.3ZW(&NF=SO?'(J#
MC4,[<GK)H>D'>\9J.M]56.@T 6G5TB 8)F)>XU#3%\QUT@W9'6@[0(64(3?;
M?LSU?(LBZC&:SU@RH33ZGE+C(M<[5_18K&M4W Y*\$YM]]35%9?RU2B1_(D3
MZG]=>ACOS,/XZ]+#N/0P+CV,#^J\'RY\WI\U,S+GUNKQ$7]%HW ZZ@QPQPRV
MN&L#$T@-<$*83]?DF+6,[]E)+9ZGZMWF9:LVP LZNA)2%G<"Q[,%N?'K%X\Q
M_ ?G_QIGI[,U+Y!BZUYJJ7A',:=4FID[EP5"[)KK3 8I*0"H-\QDR9K 9H<Z
M+JUNFA70A%& 5,NEL]IY5&+LDUBS0RWIZ$$[JQQYG3&I.;.DT.P*7IB?LH5N
M:T(2['JPEW8?V@3_$.&@+[$Z(.1]\->YT6G)X<-3Z8+)U6U&LLD=N?@\V'4"
M"]$L&U&(@,;UK>9),-]1H<;2S<1L[E[_R*'C=**5D?X'6X&; P(#Y!XQAL'!
M*2TU>'V8>"%L/TT5(T ]0]]1>IZ7W9Q3$VY,),6,JDJ"^::ZNC1]E>"WJJ8D
M8SOPKMN"0'9 FDR2E>;>'!F<4"&_1M38\Q(&F09K.UM_LVAVNZ:8P=&"()'+
MYHPTKMX$%IOZKK+-6+5;U5#W7V[G:>$[6H)@+=G4FR$A2<-UN-<J3FI:10]D
M#]X:\Q704?9>?X7-JM!6^*! SX[.P1RNJI)@FZ46R,YZ=<7Y)!LHXVT!TVPN
M:U_:]>$9:%@G[5'?3)=R,H*+S% 2(8NS&7)-QY$&7)/-8.CT:3;L\#5V[W6+
M1G0"\: ^=O;20N<3&^<R]\SF*Q\9-<<=O8M/HG7(>WKEGW]H"RGMSSVSNP--
M)T')&=E=(<)30&G#)U3S\/5<UEX2*(@2KZ:$JYZ"3A)NU'+(,=48@8>G_L2)
M;K(EUK0AQ";G=U%^=%)@WX'&,=Y6"-S0>%##,YYMD78S[QD\ >-YMPQOY&A;
M%T'7 DGOYAJT ?B<A!BBKP^VK1&)0"%.*>)X0I@=:$8F/-V%9B;:6*MMQ!Z&
M =A3U&R!#<*ZP$-Z:K!)W6N!G(6'X8Q-"P"> 0UCYSM_70U6(9T((-/+2DK/
M+OSELHKH#%!A,@,=P^,[-%EIZ4?KZ5YP,SAH(M5%W,L[[Q"W*&C+H0"CKN%R
M8R&<I66<!K;F6;>OR5.0=[7+Y2>>>3,).U0CIQ;A:&W5R!/?" OI!/@MX#'2
MO]N+]Z6Z-[+\.UI?HV^ROGJ@5V" Q;2A,! <1Q:"@VVP&Y3F787A,<\(ZFH>
MM"PV^X$XC%?23"^;7H6M=*V>Z*7L6'PTJ;*P#65._<3=D$ODUT,Q"J2X7D0I
M*+<I0@YN[T@?K=(3I#/D]\#@WA\J)=V E'S<IBN1FN:3R-"12' #"I%"GC:)
M+"V-^U/FU7G0M)">Y+"9V<>FJD_:""63J#%%OLC<]4B*",@CK-45["2Y)(7O
MK*B<+ZRHG.J)DBZ'!EB#M9'3<^K.X"0'HCL4"1E(,[%@3Q>/FY[D+K06"1%?
MX-F#.;/DJ+D@_Q*CMF!>4RRZ\CR %C<Q)D65EGD#WZ7*[UB[N<NXZHME7/7.
MXJHOEG'595QU&5>]+P?F3='RX5!\7X\GP6D]AMD95*MC!C_"D_&^'"M_QK&S
M0WK$3,^-G?GN'O6#^Z+8/B<"$,?-/8>WIGN(TB$Z!PB4(,5=+V'7+9;9ZHK!
MO (ACH6X.1&V<:/@M5C5T%OORB#+,KREW6YC[4W7Q146X%8"/,9P"<V6WF;V
MS]<&ZX+@'ZP!I6*T#&DR#)[RO!:9R/IM$],<2KHOI#OX8:3[G8DVN9I<'9"=
M(]=??C2Y4G/?OP:Y_A0'W\)E/<=%O@&6HD&<G*@D-J6+0@\#GQZ& KU 0))(
M@8X!J&5Y(V&=T-CJP>\"H."3SR[UCS/-TML^\783$]"(F_.\ L!N4N14A6F=
MXL6X3N&VX&NP__C)LU\$0N8-8CM(&\#2?UU>AV\G:\XDW@]:3\]J;+^)3Z&
MG29;B1L9LDA)=1;#FM+"^NB6?E_.TIGUUW7Y:I<;+=TS]\=3=VQ04EL9;$@X
MR D:KD\('DDS@@7&6+GC8TB0H=@.*(F2B?([6+:CR2.@H0F(:956YV$04U\>
MSE21TCS&(94.'S/PHG@A 7YPJQW,!4RGTF>GRET3.GH';T*<OE4B/BU&L5WK
MQWPXU 32:/!/'8T/=:P1$B55EYC\,D80W^!+ABU 04H8I^71FY->:+A^I@L9
MHO$2NID@F+:\XS/,LKI"Z"+T5! :>IS4X](D*DFZ5<&K8)J?"4+ONM=X#[@U
M332!M)(C'=[R90"G.I,_7?%UDCB>I6G3D,?F5"?UP'?8,V)D&("8=(^A/7&O
MQ C 'JE@>#TK<G@C(8?FQN.+/(9E:&X]DA2%F$"WD#>&8:/YPZ[)8^92*;:+
MFTS 3L;"PW6$I,GR(,TS;&YJ;Z!0%BU"A-5+8/R&5-VY%GLC>YD='9BDNC2$
M)QB\'A0,RDA*6Y-6M 4'::FLDHI0$J)TK'OD1:+EH/)UJZ+A#(YAUU"4 KM6
M<G0A.?0PZR&FPLH]9,8>'S8[6]M;_/YC7(TXM'WX1G42DR)'Y#F"TXBSQ."D
M@J-IQ""BMK/5ZLH:NM(T5>UATUKO# 11V6LD>OG" X]/8DU*D&D&&G&H"3;$
M!2ER?@WU<*BG32&.)1 9CI[BP +/J36OH8(@TG@>5NRX]8:P,F-&7'3B)3?E
M!!',9D,8&!XB#=L(!D:._KIN6^W^"66]8:1UFYBBK+3#9J@9))C_B2IWYUD]
MBRQ-FOFT,7$&K[YE,X.GK-$SAKF.:]N_+CII6(\V:/H]\9K<@3-^>VOIC;\S
M;_SVUM(=OW3'_X7<\;>4V/>LPXDVUX-VE@?J(@>#/ZY)9;.X$C.>TI)1.XQ3
M")T$GL+EH0?:_$;0]M$7H$8(L<'E1,ZC9:!C287#0@6\X=)!4SA(^-45I^$T
M2CU8\6C;/+,I=*A\@0Z""B/H9C*6BO.):6[/VMKM=;R>R;"\?A_NKB_ZSM8#
MZHO^F\[(2CS1J1:E;B]5R;CD+NF'S3SE0/3>%@Z-\G!H@%)GO*S<AM;69]BV
M:>2I<1I51VW)F@!U$A2#:ZK1E>:P3E:\S1Q&'&;3:5,SN:,[#>D69F?Z_MI:
M(]84FW8E<:<UO,#,N##U.I)%;BK1E =/XUTEP.*$,S^"49OY9;16JRO"G4^V
MT!!3TU;%W&PC&51=YVX:=1NFI6Z7W*QU%L5H[.N@U]F#T3(0C:,/8:A4=(X9
M2F4 %-/_>IX,DBIX@Q3"R^AOV6:P=M"J0NL '^#NVH77*'EU!3OOP.-<<V76
MJ0MY2=.5"!8X*059B#/W,"]<11&H:[!LZ71S/;#.H-865@GU1Y8^R$R:UKL*
MJT I6-(-")9OK,5OVDW'9D8DNI% K0O*[[J!#MR<^P4V85M39"7,D.>YK0UJ
ML(VH,$%57H)J-=T8T@X^_863]=M5E2UW JX)3U1HG7VE;9II%9.)70UK<!7!
M8PD&\8B^.?%O!KW&>85.;X^ZT=6$"XHM?=@OB_@6S)32]40**L)6<RC;*"@0
M"O( ,.83/4L'U<HEQD;:5[J UQI=@? -.ZQ05,B,]P1'B#V23I,A9OF5-:T"
MH2C'>JBI?+.%REL4>/#2L+:]E'=R6WM?^@=(@ 'KBTTUS7P;5_P,1XQ[9;FW
M;%3S472,:EW=]["^[9G@"<#=U-=O[\B_P8%[=T=]=R>2YUM[V(ED9_N>ZP%-
MFTM4>*,8[&'U=>+:!YP@[R5:] )/O$7H4TYU/#+NPUF&0$]9PE"$4LK*M9T&
M/ L.;G'*$-(:>U:!?Q(P0 ER&Z0D>E&9\$;<RTB/02I%=9JH(KA0:2TNF#0O
MR<7&UT8JDY)IK_@(23S&N&^%,M@R'>HC0SJ3 JP!B4QE;JHN0UN*/(,6CG$O
M8@ IEY40;O.DGW&LES4Z[H,$V!X]JRAMX37'(?L)Q22P;V$.FF0\@;<SGC]5
M1KQ'FZ@+F=.O.9@U'4RN)\4\$O2(<""BI$JUQ#1J8DT ]JO$N3? O4U7DBBO
M"P&$AX6C,FMLCU+&# X?!CIAH)]J3J,>80^,2_!JLY"AB>0#?"'0!=1869SU
M!F9;.ZS)S=QT]GON%[ASJ [#'DE5&<45.[_ 1?.>Q;T*"Z'SU941B%_I136C
M&C61'5#OK,?D@Y:($W[42LTU#_8Z^ZD+E:2FRV#C-":J(_^]79]-S\K^>23L
MSLZ#$**^274 KS7.$"_2%IG=AV/Q@4>+MZ\XA:\((<^Y94TMCB%HF5*"0<WX
M\HR$97G:( '#WA@<Q388@DXQ0>VL$O30?0T<CV(#Y2)A",[M>AF0YI=R10I8
M4 ("3,)W,(7[2QLF,QB$ A.\8?KK81@HM$ >U"@5M/[I9G#@A%;(QZ&/WHIR
M"<Y1//=@+8*U)^N46V$JWJ[I23MLE.'-'E.('"M(K8SPG1<" Y$/82G1DH'3
MGA5IIT++U$7=;NNF=GL8<IFM6 O\@/B=J'@?$]SVIH2[?FCXY882]T>,O5"@
M9GL9J+F[0,WV,E"S#-0\W$#-4F&YL<)RI2E%#>07[\3JG_$,8R8)J"7!M()E
MEZK"^E_-&8V&[< !IS.LEZ<2(79-XKO/T"P>*T*F(N<0]S^DY!,$Z<I851KH
MUD42B&IDJ8H-ZF>HKMFZV9*]>/:I9#:!K8=)I$ILTA(L*''1RK,P9965H^0B
MP6X=G,$$OS6]M-1B#)0VZE%/7OO)1*<I^>(+UJ_647]C_X(#M$-CD]=E>[WI
M*T-H.IJT38(+C8(36L4'QAF1FH3H=76*2&K29Y038)4!^/6VB!9X;0<SQ&@-
M+I6 AZ']6XDSG0#K6S?B&MY\+E>29'.BTB^>M5'N;<*338AH6AM.L8RK]CK"
M"S"6 QP=A^:E&CM%L9ZDG-28!!11W!)=X5/RL""ET->4*C=UJU+87XDE\&'C
M/)NRGX+:VW.NHE V>Q^ZR%EP ("-J'"\IA6GQR/EE)0#U0&:P^XQXVEQV=9Z
ME.,FFEA)X#K8VZV'/[)NO5=,$8J&Q &B[I"O">&/;/C)ZQ=^G:'B!0C8,^9%
MHPW^7Y27Z%DR7>Y#J[=+1V;RTF'['-L(!?:EX5DWV>\@AHM,.]-GJ/%QIO\?
MIO#:?KQF-+:*&I0 7ZB4 1R1D-#II;ZRV]Q^);C7$D4W,1W>4OH+,W!U57'[
M(,PH$]!% COD/%Q<'Y'$'LL3GE$F84[R&.*KAH'$-OUVF408[&6[8@5A1+.
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M,&638?ETZT7/G>GQ#ZXS>:B!CIUEH./N AT[RT#',M"Q#'3\3.K#8&'U84_
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MH.$M2]#=M?R/56)J.LS3QTK7L#'XCD^G&7 _I/:,7]E4&2U&94:>A"A -EJ
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M*JSASDNM.+;P+U"T_EOICP85H>U[SWN_YS/6+7G@AH6WI2MU;4\5'J6Y5;%
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M<=+RBSI8'$.RZ7Z+"L\(&&9!YN1$VMK]^)0IF-@$XN1 S#H7(0G]B_K,.B+
MK%"N<5O* EF+GM<5^S&\I&H4_0T;9](FNYU=OS\.&^\%:"W6B/?F?OF":PK8
M")T6V/9E84U:6^%<(.0.S@W81.Y0N,I'Z!D):W!'709D[C-LF>T!0"D0!FQ
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MD#OL$'*^.EB_H@MU6E)UJ*5&S2L[?-L^(!ACPCA)(:>E#3GUF) 4!%U7JXJ
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MM^&B;*['XX[><4@P_67,U:S*UT(O[P;#-0?+LJ!FTRT08'W,&_=>^<1@R.!
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MLD8W!?YE>'O ^ 'Z*9NO)QGB0#DK1Z2)L=@D$6BRFN$GU%80=0AXN!P<(WF
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M0(0)LKE;_M>P/8]#.K8)-EP=\70:C!-$D2Y@W/0X["DT@G_YH2DW#08;()-
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M%*LNL7@IUCT5SU!S5EXI")<W978!W0B9)&YAU"K=0%<EW E^@:AF9+MM%KG
MI",LF>H/!/U,-1U$4RJ]Q"1?+N\&[\SSLMKR,VM<T8M W +P=L848JNV R>J
M%A\/L0ALA24:A"G#]]0)IQ5K'GS\9Q%*,.<;I()%UX6T#<_'QAE>SR?UFT)7
MP<G<A=PA"#\YON;=:GZQ*%/V'N\C:912YK5<BIN1*VUQC;6DG,GRMJ5XZ!48
M]ZX>&>ZOL:)^0L^JO"SK8,*0-2SLC/E1T-^<FWB/&7.PTA*%,,?P:(RPAN'
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M  !T=C4R.3@R.5\X:RYH=&U02P$"% ,4    " "5A#1/QL9&(X!6  !A!@(
M$P              @ '7,P  ='8U,CDX,CE?97@Q,"TQ+FAT;5!+ 0(4 Q0
M   ( )6$-$]E4O<48S@  , G @ 3              "  8B*  !T=C4R.3@R
M.5]E>#$P+3(N:'1M4$L! A0#%     @ E80T3]@*T.P"*   D+D  !,
M         ( !',,  '1V-3(Y.#(Y7V5X,3 M,RYH=&U02P4&      < !P#%
) 0  3^L

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>16
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M'WYW83MJ<S3_V/@FV+7PZRZZ+U!+ P04    " "5A#1/F5R<(Q &  "<)P
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MZ*!Y$QHON)Q:KSF+(?&,[Q]&CV+IP9B%8._NE73BCQS#]\Q_ %!+ P04
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ML)\)VV$]=N'?(*EA.N_6_VATF<N@7?S-R$=*[4%?#?_)\@M02P$"% ,4
M" "5A#1/'R// \     3 @  "P              @ $     7W)E;',O+G)E
M;'-02P$"% ,4    " "5A#1/)^B'#H(   "Q    $               @ 'I
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( )6$-$]V61:=[@   "L"
M   1              "  9D!  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   ( )6$-$^97)PC$ 8  )PG   3              "  ;8"  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ E80T3P)L%+:1 @  +0L  !@
M         ( !]P@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   ( )6$-$]8@Y'E-@(  )4%   4              "  ;X+  !X;"]S:&%R
M9613=')I;F=S+GAM;%!+ 0(4 Q0    ( )6$-$^ZH3F*UP$  #(&   -
M          "  28.  !X;"]S='EL97,N>&UL4$L! A0#%     @ E80T3S #
M][XW 0  (@(   \              ( !*!   'AL+W=O<FMB;V]K+GAM;%!+
M 0(4 Q0    ( )6$-$__P"8(O0   (4"   :              "  8P1  !X
M;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( )6$-$\+C]@#
M(0$  %<$   3              "  8$2  !;0V]N=&5N=%]4>7!E<UTN>&UL
64$L%!@     *  H @ (  -,3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6629008336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Sep. 16, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 16,  2019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">uniQure N.V.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001590560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">P7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Paasheuvelweg 25a<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Amsterdam<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">NL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">1105 BP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">20-566-7394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary Shares, par value &#8364;0.05 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">QURE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>97</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tv529829_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://uniqure.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tv529829_8k.htm">tv529829_8k.htm</File>
    <File>qure-20190916.xsd</File>
    <File>qure-20190916_lab.xml</File>
    <File>qure-20190916_pre.xml</File>
    <File>tv529829_ex10-1.htm</File>
    <File>tv529829_ex10-2.htm</File>
    <File>tv529829_ex10-3.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
